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In recent years an association between Tropical Spastic Paraparesis (TSP) and 
HTLV-I has been demonstrated. Based on this observation a clinical, laboratory 
and epidemiological study of this virus and TSP was undertaken in Natal. Antibody 
positive patients were investigated according to a myelopathy protocol. The 
associated disorders of peripheral neuropathy and polymyositis, and co-infection 
with the human immunodeficiency virus (HIV 1/2) were also investigated. Spinal 
cord pathology was evaluated in one patient. The epidemiological arm of this study 
was a survey of HTL V-I seroprevalence and the risk factors for exposure in the 
Ngwelezane district, north of Durban. 
Ninety Black patients with HTLV-1 associated myelopathy (HAM /TSP) were 
identified, 31 men and 59 women. Their mean age was 43.5 (.±. 12.5)years. The 
duration of symptoms prior to presentation was 6 months or less in 62% of the 
patients. Apart from symptoms of weakness (96%) and stiffness (100%), bladder 
disturbance (81%) and backache (67%) were common. A large proportion (55%) 
were wheelchair bound and sensory deficits were noted in 64% of the patients. Ten 
patients were treated with corticosteroids without benefit. 
Common laboratory abnormalities included anaemia (59% ), raised ESR (71 % ), 
polyclonal gammopathy (80%) and CSF pleocytosis (66%). The peripheral blood 
lymphocytes of 10 patients were subjected to culture. HTLV-I was isolated from 
6 samples. HLA typing in 56 patients did not show any definitive trends. 
11 
Muscle biopsies from three patients with disproportionate proximal limb weakness 
showed an inflammatory myopathy. Sural nerve biopsies of another six patients 
showed features of axonal degeneration and regeneration, demyelination and 
remyelination, and globule formation. No viral particles, protein or proviral DNA 
was detected in the biopsied muscles and nerves. 
The spinal cord from a transfusion related HAM/TSP case demonstrated 
perivascular infiltrates, myelin pallor and axonal degeneration. No viral particle or 
protein was detected but the HTLV-1 "gag" gene was amplified from the spinal 
cord. 
Co-infection with HIV-I was noted in six patients in whom myelopathy was the sole 
neurological manifestation. 
HTL V-I seroprevalence amongst healthy individuals in the Ngwelezane district was 
2.6%. Seropositivity increased with age. No significant association was 
demonstrated between infection and the risk factors of gender, history of blood 
transfusion, scarifications and number of sexual partners. This thesis confirms that 
HTL V-I is endemic in Natal and is an important cause of neurological disability. 
Future research will be directed towards (1) a detailed study of the pathogenesis 
of HAM/TSP (2) evaluating antibody negative cases of TSP and (3) determining 
intra-familial spread of the virus. 
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Spastic paraparesis without evidence of spinal cord compression has been described 
from a number of tropical and sub-tropical areas including Jamaica (Cruickshank, 
1956; Montgomery et al. 1964), South India (Mani et al. 1969), Seychelles (Kelly 
& De Mol 1982) and Colombia (Roman et al. 1985). It is an endemic disorder and 
was first referred to as Tropical Spastic Paraparesis (TSP) by Mani et al (1969). 
TSP must be distinguished from epidemics of spinal disorders such as the cassava­
related myelopathy in Mozambique (Casadei et al. 1984) and lathyrism in India 
(Prasad & Sharan 1979) as well as tropical ataxic neuropathy (TAN) (Montgomery 
et al. 1964; Osuntokun 1968). The clinical features of TSP include a subacute to 
chronic progressive paraparesis, frequent sphincter disturbance and insignificant 
sensory disturbance. Some studies showed equal frequency of disease in males and 
females whereas others observed a male preponderance. Most studies indicated 
that the disease tended to stabilise and the disability to be seldom severe. TSP 
represents a major cause of neurological disability in the indigenous people of the 
countries mentioned earlier. For example, Kelly & De Mol (1982) found a 
prevalence ratio of 127 per 100,000 of the population in the Seychelles. 
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The Natal/KwaZulu region (henceforth referred to as simply Natal) constitutes the 
smallest province of the Republic of South Africa and lies between the latitudes 
27-31°S and longitudes 29 - 33°E. It is bordered on the east by the Indian Ocean
while the Drakensberg mountains form the western boundary. TSP was first 
reported from this region by Cosnett (1965) who described 41 cases comprising 
mainly young adult males. In a later series of 330 black paraplegic patients in 
Natal, Wallace & Cosnett (1983) noted that TSP was the most common diagnostic 
category after trauma and vertebral tuberculosis, again emphasising its importance 
as a cause of neurological disability amongst the indigenous people of the tropics 
and sub-tropics. 
When the Neurology Unit was established in 1985 at Wentworth Hospital in 
Durban as a referral centre for Natal, a myelopathy protocol (Appendix A) was 
drawn up to study TSP in greater detail. After a clinical assessment extensive 
investigations were undertaken. The battery of tests were reviewed at regular 
intervals. Where a test yielded no useful information it was deleted from the 
protocol except in special circumstances. Despite the in-depth study it was noted 
that up to one third of the myelopathy cases still remained undiagnosed 
(unpublished data). 
1.2. HTLV-I INFECTION AND DISEASE
The aetiology of TSP remained elusive. Treponemal infections, toxins and 
nutritional aberrations were postulated but were never proven. 
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The human T-cell lymphotropic virus type I (HTLV-1), the first human retrovirus 
to be identified, was isolated from a patient with cutaneous T-cell lymphoma 
(Poeisz et al. 1980). HTLV-1 was then linked to other cases of adult T-cell 
leukaemia/lymphoma (A TLL) (Yoshida et al. 1982; Hinuma et al. 1982). In 1985 
serendipity led Gessain et al (1985) to demonstrate antibodies to HTLV-1 in two 
patients with TSP. This association between TSP and HTLV-1 was rapidly 
confirmed by others. In the Seychelles, Roman et al (1987) found antibodies in 17 
(85%) of 20 serum samples from TSP patients, whilst Rodgers-Johnson et al (1988) 
detected HTLV-1 antibodies in 82% of 47 Jamaican TSP patients. The Colombian 
experience was similar with 52 of 55 (94%) patients testing positive (Zaninovic et 
al. 1988). 
Osame et al (1987) described similar cases from Japan 'and called it HTLV-1 
associated myelopathy (HAM). Since HAM and TSP are the same condition, the 
disorder is now commonly referred to as HAM/TSP. 
Following the initial studies, testing for antibodies to HTL V-1 was included in the 
Wentworth Hospital myelopathy protocol. This thesis represents the clinical and 
sero-epidemiological experience with HTLV-1 infection and disease in Natal. A 
total of 90 HAM/TSP were collected up to December 1991. Chapters 2 to 4 
describe the clinical, laboratory, virological, neurophysiological and HLA findings 
in these patients. Chapter 5 describes in detail the spinal cord pathology of another 
patient. Chapters 6 and 7 discuss other HTLV-1 associated disorders viz peripheral 
neuropathy and inflammatory myopathy. The interesting occurrence of co-infection 
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with HTLV-1 and the human immunodeficiency virus (HIV) forms the basis of 
chapter 8. Chapter 9 discusses the sero-epidemiological study of over 1000 
apparently healthy blacks. The thesis ends with a look into the future. 
ATLL has been seen in Natal (Jogessar et al. 1992), but is rare in comparison to 




HAM/TSP: CLINICAL ASPECTS 
2.1. DEMOGRAPHIC FEATURES 
From August 1988 to December 1991 a total of 90 patients were seen at Wentworth 
Hospital. They were referred from all parts of Natal and included 6 patients from 
the Transkei which is an adjacent independent Black homeland (Fig.2.1; Table 2.1). 
All patients were Black. 
There were 31 men and 59 women. The mean age at the onset of symptoms was 
43.5 (± 12.5) years. The youngest was 18 years and the oldest 70 years (Fig. 2.2). 
The duration of symptoms prior to referral to Wentworth Hospital ranged from 1 
to 144 months with a mean of 14 months. In 56 (62%) patients the duration of 
symptoms was 6 months or less. A further 9 (10%) had an illness duration between 
7 - 12 months. Of the 47 patients questioned, 10 (21%) had received blood 
transfusion in the past. Thirty four patients were asked about the number of sexual 
partners engaged. One denied sexual activity, 19 had a single partner, 8 between 
2 - 5 partners and 6 more than 5 partners. No patient had a family history of a 
similar problem. 
2.2. SYMPTOMS 
The main neurological symptoms are summarised in Table 2.2. Apart from 
complaints of weakness and stiffness, bladder disturbance (81 % ) and backache 




The main neurological signs are summarised in Table 2.3. Weakness and spasticity 
were present in all (MRC grading used for power testing - Appendix B). Sensory 
abnormalities were common ( 64%) and a large proportion were wheelchair bound. 
2.4 DISCUSSION 
2.4.1. Area of Residence 
The patients came from all parts of Natal but especially from the coastal 
and northern areas. The relatively fewer cases from the South Coast and 
inland areas may be related to poorer health facilities and non referral 
(personal observation). 
2.4.2. Race 
All patients were Black (84 Zulus and 6 Xhosas). Apart from a specific 
situation of transfusion related HAM/TSP in a White patient (discussed 
separately - chapter 5), no case has been seen in Whites and Asians. The 
occurrence of HAM/TSP almost exclusively in people of Black African 
ancestry is a world wide observation (Roman 1988). Gallo et al (1983) 
postulated that the chronic viral infection originated in Africa and spread 
to other endemic areas via the slave trade dating back to the sixteenth 
century. This suggestion does not explain the high endemicity of HTLV-I 
amongst the South-western Islands of Kyushu and Shikoku in Japan. 
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More attractive is the hypothesis that the virus existed in man since pre-
historic times but died out in all except a few groups of people (Ishida and 
Hinuma 1986). 
2.4.3. Age 
The mean age at onset of symptoms was 43.5 (.±. 12.5) years. The youngest 
patient was 18 years and the oldest 70 years. Symptoms began after the age 
of 30 in 83% of the patients. These findings are similar to those reported 
from other parts of the world (Montgomery et al. 1964; Vernant et al. 1987; 
Roman et al. 1985; Roman et al. 1987). While the findings on age dis­
tribution confirm that HAM/TSP is a disease of adults, it provides no 
information concerning the incubation period. The data obtained regarding 
blood transfusion, age at first sexual contact and number of sexual partners 
are inadequate and no reliable conclusions can be made. 
2.4.4. Sex 
While both men and women can be infected, earlier studies showed a 
preponderance of men. For example 53% of the Jamaican cases 
(Montgomery et al. 1964) were men and, in Natal Cosnett (1965) found that 
66% of his patients were male. More recent studies, however, show a 
reverse trend with a predominance of women (Vernant et al. 1987; Roman 
et al. 1987). The present study found a female dominance of 2: 1. Possible 
explanations for the present gender pattern could include case ascertainment 
bias e.g. women may seek medical attention more often than men or may 
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have more severe disease (Roman 1988). However, it could be argued that 
in Natal the observed male preponderance by Cosnett (1965) could have 
reflected easier access to hospitals for males because of the previous 
practice of migrant labour. It is also noteworthy that the virus is more 
effectively transmitted from male to female than vice versa (Kajiyama 
et al. 1986). 
2.4.5. Familial Cases 
The 90 HAM/TSP cases were unrelated and none had a history of a similar 
illness amongst family members. It was not possible to personally interview 
family members as many patients were from far flung areas and had lost 
contact with spouses, partners, parents and siblings. Thus an in depth family 
study was beyond the scope of this thesis. 
2.4.6. Disease Duration, Severity and Pattern 
Most of the patients had a short duration of illness (72% less than one year) 
and approximately half the patients were wheelchair bound or bedridden at 
the time of presentation. These findings differ from other studies which 
showed that most patients remain ambulant with or without physical aids 
(Rodgers-Johnson et al. 1988; Zaninovic et al. 1988). The course of the 
disease is therefore more rapid and aggressive in this study population. The 
reason for this is unclear but may be due to a high viral load ( chapter 3). 
Unlike other studies, 64% of the patients had some form of sensory 
disturbance on examination. A pinprick level could be obtained in 
52% of the cases and patchy or peripheral sensory impairment was 
noted in a further 12%. This may again reflect a more aggressive 
disease in our patients. 
2.4.7. Therapy 
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Japanese studies have demonstrated that the myelopathy responds to 
steroids, other immunosuppressive agents and plasmapheresis (Osame et al. 
1987; Matsuo et al. 1988). The occasional case report from the West has 
also suggested steroid responsiveness of the myelopathy (McArthur et al. 
1990). 
In an open study, 10 patients of the present series were given prednisone 
(lmg/kg body weight) for periods varying from 3 to 9 months. Two were 
ambulant with aid and the rest wheelchair bound. No improvement was 
noted in any of the patients. It is probable that this group had too far 
advanced and irreversible disease to show any response to steroids. 
Area 
Bizana 
TABLE 2.1: AREAS OF RESIDENCE OF PATIENTS 

















































































































Map of Natal and Transkei showing areas of residence of HAM/TSP 
cases. Note patients come from as far north as Ingwavuma and as far 
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TABLE 2.2: SUMMARY OF SYMPTOMS AT THE TIME PRESENTATION 
Symptom Number Percentage 
Stiffness of legs 90 100 
Weakness of legs 86 96
Urinary bladder dysfunction 73 81
Thoracic or lumbar backache 60 67
Numbness 59 66
Paraesthesia 57 63
Bowel dysfunction 41 47
16 
TABLE 2.3: SUMMARY OF NEUROLOGICAL FINDINGS 
Neurological Finding Number Percentage 
Lower Limbs 
Spasticity 90 100 
Weakness 90 100 
Brisk knee tendon reflexes 80 89 
Brisk ankle tendon reflexes 65 73 
Upper Limbs 
Weakness 31 34 
Increased tendon reflexes 70 78 
Abdominal Reflexes ( recorded in 80 
cases) 
Absent 76 95 
Plantar Response (recorded in 87 
cases) 
Extensor 70 80 
Equivocal 10 12 
Flexor 7 8 
Degree of Motor Disability 
Ambulatory without assistance 19 21 
Ambulatory with walker or stick 22 24 
Wheelchair bound/bedridden 49 55 
Sensory Disturbance, Lower Limbs 
Impaired pinprick & touch 55 61 
Impaired proprioception 27 30 
Impaired vibration sense 28 31 
Approximate Sensory Level (recorded 
in 89 cases) 
None 32 36 
Lumbosacral 11 12 
Lower Thoracic (T9-T12) 18 20 
Mid Thoracic (T5-T8) 11 12 
Upper Thoracic (Tl-T4) 6 8 




HAM/TSP: LABORATORY DATA 
3.1. METHODS 
3.1.1. Routine Blood Investigations 
Each patient had the following blood tests in the routine service laboratory: 
full blood count (FBC), erthyrocyte sedimentation rate (ESR), plasma urea, 
electrolytes and glucose, liver function tests (serum albumin, globulin, and 
glutamyl transpeptidase (Alpha and GGT), aspartate aminotransferase 
(ALT), alanine aminotransferase (AST), and alkaline phosphatase), serum 
protein electrophoresis, serum immunoglobulins (IgG, IgA, IgM), antinuclear 
factor (ANF), serum rapid plasma reagin (RPR) and treponema pallidum 
haemagglutination inhibition (TPHI) tests for syphilis, serum folate and 
vitamin B12 levels. Other serological tests done were as per myelopathy 
protocol (Appendix A). 
3.1.2. Cerebrospinal fluid (CSF) tests 
CSF was sampled for cell count, protein, globulin, glucose, bacterial culture 
and serological tests for syphilis. Selected cases were tested for cryptococcal 
antigen and cysticercus antibodies. To assess immune response and de novo 
antibody production within the central nervous system compartment the 
following tests were done: (1) concentrations of CSF and serum 
,82-microglobulin (,82M) were assayed using a commercially available solid 
phase radio-immunoassay (Phadebas ,82-microtests, Pharmacia, 
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Uppsala,Sweden) (2) calculation of the IgG index according to the method 
of Lefvert and Link (1985) and (3) detection of CSF IgG oligoclonal bands 
using the method of Kier et al (1990; Appendix C). 
3.1.3. Virological Studies 
Specimens of blood and CSF were tested for the presence of antibodies to 
HTLV-1 using an enzyme linked immunosorbent assay. All positive 
specimens were subsequently confirmed by Western blot (WB) (Dupont 
HTLV-1 ELISA and Dupont HTLV-1 Western blot, Biotech Research 
Laboratory, Rockville, MD, USA). All blood specimens were also screened 
for the presence of antibodies to the human immunodeficiency virus (HIV) 
by ELISA and any positive result confirmed by WB (Abbot Recombinant 
HIV 1/2 EI
A
, Abbot Diagnostic Products, Weisbaden-Delkenheim, 
Germany, and HIV 1 Western blot IgG Assay, Diagnostic Biotechnology, 
Singapore). 
Virus isolation was attempted from 10 of the HTL V-1 seropositive patients 
using methods previously described (Becker et al 1988). Peripheral blood 
lymphocyte (PBL) cultures were established from heparinised venous blood. 
The criteria used to determine HTLV-1 infection were (1) the establishment 
of a continuous long-term cell line with the morphology of lymphocytes 
transformed by HTLV-1 infection, (2) the demonstration of characteristic 
morphogenesis of HTL V-1 particles by electron microscopy of ultra-thin 
sections of these cells, and (3) specific hybridization of DNA extracted from 
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these cells with the reference HTLV-1 DNA probe kindly provided by R. 
Gallo. 
For comparison serum HTLV-1 antibody testing was also done in a control 
group consisting of patients with other neurological diseases, patients 
admitted for plastic surgery and trauma cases admitted to orthopaedic 
wards. 
3.1.4. Radiological Studies 
All patients had chest and spinal radiographs and all underwent 
conventional myelograms. Myelo-CT and CT head scans (GE9800) were 
done in selected cases. 
3. 1.5. Electrodiagnostic Studies
Motor and sensory nerve conduction studies were performed using standard 
techniques and taking the necessary precautions to ensure consistent results. 
A minimum of 1 motor and 1 sensory nerve each in upper and lower limbs 
were evaluated. Full field pattern reversal visual evoked potentials (VEPs) 
and brainstem auditory evoked potentials (BAEP) were also done in some 





3.2.1. Routine Blood Tests 
Anaemia was present in 33/59 (56%) females (haemoglobin less than 12 
g/dl) and 18/29 (62%) males (haemoglobin less than 14 g/dl). The 
haemoglobin was not measured in a further two males. The mean ESR 
(measured in 87 subjects) was 50 mm/hour with a range from 1 to 157 
mm/hour. Sixty two subjects (71 %) had an ESR of greater than 20 
mm/hour. Leucopenia (less than 4.8 x 109 /dl) was present in 9 (10%) of 88 
subjects tested. 
A polyclonal gammopathy was seen in 63/79 (80%) patients. The serum 
IgG (normal 0,7 - 3,1 g/1) was elevated in 60/71 (85%) samples, IgA 
(normal 0,7 - 3,1 g/1) was elevated in 60/71 (85%) samples, and IgM 
(normal 0,6 - 2,7 g/1) in 38/71 (54%). 
The serum RPR was positive in 20/89 (22%) samples tested. In only 2 of 
these was the titre > 1:8. The TPHA was positive in all except 1 of 20 RPR 
positive cases. Antinuclear antibodies were detected in 8/78 (10%) samples. 
The titres were less than 1: 100 in all except 1 case. 
3.2.2. Cerebrospinal fluid tests 
The routine cell count, protein, globulin and glucose levels are summarised 
in Appendix D. Pleocytosis (>5 cells/µ!) was present in 60/90 (66%) 
samples and an elevated protein ( > 0.4 g/1) in 34 /90 (38%) samples. 
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Bacterial culture (including M.tuberculosis) of CSF was negative in all 
samples. No patient had a positive CSF fluorescent treponemal antibody 
test. Cryptococcal antigen was not detected in any of the samples tested. 
Appendix E summarises the results of IgG indices and CSF IgG oligoclonal 
bands, whilst Appendix F illustrates the serum and CSF ,82M levels and the 
CSF: Serum albumin ratios. The IgG index was calculated in 59 patients 
and was greater than 0,7 in 43 (73%). CSF IgG oligoclonal bands were 
present in 23 (85%) of 27 samples tested. Figure 3.1 illustrates some of the 
positive results. The serum ,82M was raised in 24 /25 (96%) and CSF ,82M 
in 25/25 (100%). The CSF ,B2M was greater than the serum ,82M in 17 /25 
(68%) paired samples. 
3.2.3. Virological Studies 
The ELISA and WB was positive in the sera of all 90 patients. The WB 
showed strong specific multiple banding pattern indicative of well established 
infection (Figure 3.2). The 86 CSF samples tested yielded similar results 
(Figure 3.3). No sera from the control group tested positive. The virus was 
isolated from 6 of 10 PBLs samples subjected to culture. The cultures from 
5 of the samples were positive within 7 weeks and the sixth sample after 3 
months. 
Six patients also had antibodies to HIV in their sera and CSF. This group 
is discussed in detail in chapter 8. 
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3.2.4. Radiological Studies 
The chest radiographs were normal in all except 9 patients. Four had 
changes consistent with old tuberculosis whilst the remainder showed non­
specific shadowing. None of the 9 patients had chest symptoms at the time 
of the neurological presentation. The plain spinal radiographs were 
abnormal in 13 patients. All of these showed degenerative changes but 
none had changes thought to be clinically relevant. No myelogram showed 
a clinically relevant compressive lesion. Myelo-CTs were done in 77 
patients. Arachnoiditis was noted in 9 (Figure 3.4) and thoracic cord 
atrophy in 16 (Figure 3.5). CT of the head was done in 24 patients. Minor 
degrees of cerebral atrophy was noted in 10, basal ganglia calcification in 1 
and periventricular lucencies in 1. The remainder were normal. 
3.2.5. Electrodiagnostic Studies 
Median sensory and motor nerve conduction studies were performed in 64 
patients. Median sensory latency was prolonged in 9 patients (greater than 
2.99 msec; stimulus to onset), velocity decreased in 3 patients (less than 36.3 
m/sec) and amplitude abnormal in 1 patient (normal : greater than 8.58 
µ, V). The median distal motor latency was prolonged in 13 patients (greater 
than 4.38 msec) but the forearm velocity was normal in all. The evoked 
motor amplitude was decreased in 12 patients (less than 7.0 µ, V) and 'F' 
latency prolonged in 4 (greater than 32.7 msec). Sural and common 
peroneal nerve conduction studies are summarised in Appendices H and I. 
The sural studies were abnormal in 33/62 (53%) nerves studied, the main 
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abnormalities being either low amplitude or lack of stimulability. The distal 
motor latency of the common peroneal nerve studies was abnormal in 12 
(23%), the velocity in 16 (30%), the amplitude in 29 (55%) and the 'F' wave 
latency in 4 (8%) of 53 nerves tested. A further 5 nerves were unstimulable. 
Pattern reversal VERs (Appendix I) showed prolonged latencies in 3 (6%) 
of 69 right eyes tested and in 5 (10%) of 48 left eyes tested. The results of 
the BAER studies are summarised in Appendix J. One or more inter wave 
latency abnormalities were seen in 13 (25%) of 54 right ears tested and in 
14 (27%) of 51 left ears tested. 
3.3 DISCUSSION 
3.3.1. Routine Laboratory Studies 
The routine laboratory studies did not demonstrate specific trends. 
Anaemia, elevated ESR and hypergammaglobulinaemia were common, all 
features consistent with a chronic infective illness. 
The serum RPR test for syphilis was positive in 22% of the patients but no 
patient had a positive CSF Ff A-ABS test. These findings differ from 
Jamaican patients who have demonstrated positivity rates of 46% and 4% 
in serum and CSF respectively (Rodgers-Johnson et al. 1988). Similar high 
positivity rates were obtained in Colombia (Zaninovic et al. 1988). Vernant 
et al (1987), however, found figures comparable to ours in Martinique. 
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Osame et al (1987) did not comment on syphilitic serology in their Japanese 
patients. The high frequency of treponemal antibodies in some of the 
studies remain unexplained but they are probably not relevant to the 
pathogenesis of HAM/TSP. 
3.3.2. Cerebrospinal Fluid Tests 
CSP pleocytosis (greater than 5 cells/ µl) and raised protein levels were 
common. These findings differ from the typical TSP cases but resemble 
those noted in the Japanese patients (Osame et al. 1987). A possible expla­
nation may be that many of our patients presented early and therefore in the 
active stage of their disease. The IgG index was elevated in 73% of the 
samples tested and CSP IgG oligoclonal bands were detected in 85% 
(23 /27) samples. The results of these tests indicate de novo intrathecal 
antibody production. 
The {32 microglobulin protein is a 11,500 dalton molecule bound to the 
class I antigens of the MHC. Raised levels are seen when there is induction 
of MHC expression on surfaces of activated lymphocytes. In this study the 
CSP {32M was raised in all 25 samples tested and was greater than the 
serum {32M in 17 cases. The CSP/ serum albumin ratio ( used as an index 
of blood-brain barrier integrity) was measured in 21 and shown to be normal 
in 13. In 10 of these 13 cases the CSP {32M was greater than serum {32M. 
These results provide further evidence of immune activation within the CNS. 
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3.3.3. Virological Studies 
The strong multiple specific bands seen on WB confirmed exposure to 
HTLV-1. The question of cross reacting HTLV-11 antibodies was handled 
by the isolation of the HTL V-I virus from the peripheral blood lymphocytes 
of 6 patients. The CSF demonstrated bands similar to that seen in the 
serum. The tests for intra-thecal antibody production discussed above would 
suggest that there was specific anti HTL V-I antibody synthesis in the CNS 
compartment. 
3.3.4. Radiological Studies 
No myelogram or myelo-CT showed clinically relevant spinal cord 
compression. However, myelo-CT showed evidence of arachnoiditis and 
atrophy in some of the cases, reflecting features noted pathologically. Spinal 
cord MRI was not done because of lack of facilities but others (Kermode et 
al. 1990) have confirmed cord atrophy with this technique. 
CT brain showed some abnormality in half of the cases studied (12/24), the 
main feature being atrophy. The finding of periventricular lucencies in only 
one patient reflects the relative insensitivity of CT in detecting white matter 
changes when compared to MRI. Both Newton et al (1987) and Kira et al 
(1988) found white matter high intensity signals on brain MRI. These 
changes were similar but less extensive to those seen in Multiple Sclerosis. 
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3.3.5. Electrodiagnostic Studies 
Electrophysiological evidence of peripheral nerve dysfunction was common. 
For example, some abnormality of the common peroneal nerve was noted 
in 58.6% of the nerves studied. The peripheral nerve dysfunction is 
discussed in detail in chapter 7. 
The VER and BAER studies confirmed the presence of subclinical 
abnormalities in other parts of the central nervous system. 
3.4. CONCLUSION 
The extensive investigations discussed in this chapter: 
1) confirmed the association between HTLV-1 and HAM/TSP
2) excluded other recognisable causes of myelopathy and
3) demonstrated that, while the thoracic cord bears the brunt of the disease,









differences in the frequencies of HLA-C and HLA DQ antigens. Interestingly A26 
was less frequent in patients when compared to controls. 
4.4 DISCUSSION 
In contrast to our largely negative findings, Usuku et al (1988) found specific 
HLA haplotypes in 70% of their HAM/TSP patients. Furthermore none of the 
HAM/TSP associated HLA haplotypes were seen in ATLL. However, Usuku et 
al (1988) did not correct for the number of antigens tested. Another Japanese 
group (Nishimura et al. 1991) found increased frequencies of HLA-A31, B7 and 
DRl in HAM/TSP patients but these associations were not statistically significant 
when their p values were corrected for the number of alleles tested. The antigens 
Al 1, Bw54 and Bw52 associated with Japanese HAM/TSP (Usuku et al. 1988), are 
not found in the Zulus. 
There is evidence suggesting that much of the neurological injury in HAM/TSP is 
immune mediated (Dalgleish et al. 1988; see also chapter 5). When this is viewed 
against (1) greater immune responsiveness of HAM/TSP patients compared to 
ATLL and asymptomatic HTLV-I carriers (Usuku et al. 1988) (2) the existence of 
class II associated auto-immunity (Todd et al. 1988) and (3) the binding of viral 
peptides by class I molecules to activate CDS and cytotoxic T cells (Todd et al. 
1988), it is possible that a more refined examination of the HLA system may yet 
prove fruitful in Zulu HAM/TSP cases. The recent molecular genetic study by 
Usuku et al (1990) showed a relationship between a particular amino acid sequence 
of the HLA DR beta 1 chain and susceptibility to HAM/TSP. Control frequencies 
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in Zulus for HLA polymorphism using PCR amplified DNA, dot-blots and probes 
have been already established. A project to determine if any of the DNA markers 
are relevant to HAM/TSP is being planned. 
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TABLE 4.1: FREQUENCIES OF HLA-A LOCUS ANTIGENS IN PATIENTS 
AND CONTROLS 
Controls HAM/TSP 
Number % Number % CHI-SQ R-R
Al 152 8.23 5 9.26 0.01 1.1 
Aw36 18 0.97 1 1. 85 0.41 1.9 
A2 449 24.30 19 35.19 3.35 1.7 
A3 205 11. 09 5 9.26 0.18 0.8 
All 0 0.00 0 0.00 
A23 338 18.29 8 14.81 0.43 0.8 
A24 110 5.95 5 9.26 1.01 1.6 
A25 61 3.30 0 0.00 1.84 0.0 
A26 215 11.63 2 3.70 3.26 0.3 
Aw34 158 8.55 6 11.11 0.44 1.3 
A26 394 21. 32 16 29.63 2.14 1. 6 
A29 270 14.61 5 9.26 1.21 0.6 
Aw74 23 1. 24 0 0.00 0.68 0.0 
A30 583 31.55 13 24.07 1.36 0.7 
A31 62 3.35 1 1.85 0. 37 0.5 
A32 37 2.00 2 3.70 0.76 1.9 
A33 66 3.57 2 3.70 0.00 1.0 
Aw43 6 0.32 0 0.00 0.18 o.o
Aw66 3 0.16 0 0.00 0.09 0.0 
TOTAL 1848 100.00 54 100.00 
R-R = relative risk
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TABLE 4.2: FREQUENCIES OF HLA-B LOCUS ANTIGENS IN PATIENTS 
AND CONTROLS 
controls HAM/TSP 
Number % Number % CHI-SQ R-R
B7 432 23.38 16 29.63 1.14 1.4 
B8 235 12.72 7 12.96 0.00 1.0 
B13 62 3.35 2 3.70 0.02 1.1 
B14 112 6.06 4 7.41 0.17 1.2 
B18 95 5.14 3 5.56 0.02 1.1 
B21 35 1.89 0 0.00 1.04 0.0 
Bw22 1 0.05 0 0.00 0.03 0.0 
B27 8 0.43 0 0.00 0.23 0.0 
B35 135 7.31 5 9.26 0.29 1. 3
B37 2 0.11 0 o.oo 0.06 0.0 
B38 32 1. 73 1 1.85 o.oo 1.1 
B39 29 1.57 0 0.00 0.86 0.0 
Bw41 33 1.79 0 o.oo 0.98 0.0 
Bw42 368 19.91 8 14.81 0.86 0.7 
B44 303 16.40 11 20.37 0.60 1. 3
B45 174 9.42 2 3.70 2.04 0.4 
Bw47 2 0.11 0 0.00 0.06 0.0 
Bw48 1 0.05 0 0.00 0.03 o.o
B51 20 1.08 1 1.85 0.28 1.7 
Bw52 1 0.05 0 o.oo 0.03 0.0 
Bw53 29 1.57 2 3.70 1.49 2.4 
Bw5I 0 o.oo 0 0.00 
Bw57 88 4.76 10 18.52 20.32 4.5 
Bw58 585 31.66 12 22.22 2.17 0.6 
Bw60 1 0.05 0 0.00 0.03 0.0 
Bw61 0 0.00 0 0.00 
Bw62 12 0.65 0 0.00 0.35 0.0 
Bw63 43 2.33 0 0.00 1. 29 0.0 
Bw70 512 27.71 7 12.96 5.75 0.4 
TOTAL 1848 100.00 54 100.00 
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TABLE 4.3: FREQUENCIES OF HLA-C LOCUS ANTIGENS IN PATIENTS 
AND CONTROLS 
controls HAM/TSP 
Number % Number % CHI-SQ R-R
Cwl 1 0.23 1 1.85 3.18 8.4 
Cw2 99 22.30 8 14.81 1.60 0.6 
CW3 51 11.49 11 20.37 3.49 2.0 
Cw4 73 16.44 9 16.67 o.oo 1.0 
CW5 5 1.13 1 1.85 0.21 1.7 
Cw6 36 8.11 3 5.56 0.43 0.7 
Cw7 151 34.01 21 38.89 0.51 1.2 
Cw8 8 1.80 2 3.70 0.89 2.1 
TOTAL 444 100.00 54 100.00 
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TABLE 4.4: FREQUENCIES OF HLA-DR LOCUS ANTIGENS IN PATIENTS 
AND CONTROLS 
Controls HAM/TSP 
Number % Number � 0 CHI-SQ R-R
DRl 29 5.22 6 13.95 5.54 2.9 
DR2 133 23.92 15 34.88 2.58 1. 7
DR3 195 35.07 14 32.56 0.11 0.9 
DR4 50 8.99 4 9.30 0.00 1.0 
DR5 175 31.47 15 34.88 0.21 1.2 
DRw6 111 19.96 4 9.30 2.92 0.4 
DR7 94 16.91 5 11. 63 0.81 0.6 
DRW8 23 4.14 0 0.00 1.85 o.o
DR9 5 0.90 1 2.33 0.82 2.6 
DRwl0 14 2.52 3 6.98 2.88 2.9 
TOTAL 556 100.0 43 100.00 
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HAM/TSP: A CLINICO-PATHOLOGICAL 
STUDY OF INFECTION ACQUIRED BY BLOOD 
TRANSFUSION 
5.1 INTRODUCTION
HTLV-1 is transmitted through sexual intercourse, blood transfusion, intravenous 
drug abuse and from mother to child through breast feeding. The latency from 
infection to disease is shorter and the disease more aggressive when transmission 
is by blood transfusion (Osame et al. 1990). This probably reflects the higher viral 
load as well as the immunosuppressive effect of blood transfusion (Manns and 
Blattner 1991). 
The clinical and pathological features in a white male who developed transfusion 
associated HAM/TSP are presented. He was not included amongst the 90 cases 
described in chapter 2. 
5.2 CASE HISTORY
A 49 year old White South African man received 48 units of blood following a 
massive gastro-intestinal haemorrhage in February 1987. Fourteen months later 
(April 1988), he noticed progressive weakness and stiffness of his legs. By June 1989 
he was wheelchair bound and incontinent of urine and faeces. Examination at this 
stage revealed normal mental state and cranial nerves. There was mild increase 
in tone in the upper limbs but the power was normal. The lower limbs were 
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markedly spastic with spontaneous clonus. Power in the legs was graded 2/5 (MRC 
grading). There was generalised hyper-reflexia and bilateral extensor plantar 
responses. He had patchy impairment of pinprick sensation to the T6 dermatome 
on the right and L2 on the left. Other modalities of sensation were intact. 
A full length myelogram and magnetic resonance imaging of the head and cervical 
spine were normal. The CSF was acellular but had raised protein (0.75 g/1). 
Antibodies to HTL V-1 were detected in the serum. Antibodies to HIV 1/2 were 
absent. No CSF was available for antibody testing. 
The patient declined further investigations. A 3 month course of steroids produced 
no benefit. His disability gradually progressed to the extent that he became quadri­
plegic, developed pressure sores and recurrent respirarory and urinary tract 
infections. He died in April 1990. Autopsy permission was limited to examining 
the spinal cord which was removed approximately 24 hours after death. 
5.3 MATERIALS AND METHODS
5.3.1. Light Microscopy Studies 
Representative paraffin sections of the cervical, thoracic and lumbar spinal 
cord were stained using standard techniques. The stains used were 
haematoxylin and eosin, PT AH, Servier Munger and Luxol fast blue. 
Immunocytochemical studies using antibodies to glial fibrillary acidic protein 
(GFAP; DAKO, Santa Barbara, CA) and neurofilament (NF; Lab Systems, 
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Research Triangle Park, North Carolina, USA) were undertaken according 
to the technique of Wiley et al (1986). 
5.3.2. Electron Microscopy Studies 
Specimens of cervical, thoracic and lumbar spinal cord were fixed in 3% 
phosphate buffered gluteraldehyde and processed for electron microscopy 
according to standard techniques. 
5.3.3. Lymphocyte Marker Studies 
Lymphocyte marker studies (Dako-Pan B, Tll, T4(CD4), T8(CD8), LC, 
MAC 387) were done on frozen sections of the thoracic cord according to 
the recommended methods (Dakopatts-Glostrup, Denmark). 
5.3.4. Viral Protein Detection Studies 
Protein A purified polyclonal rabbit antiserum to HTLV-1 and a series of 
commercially available monoclonal antibodies (Olympus Corporation, Lake 
Success, NY) were used on paraffin embedded tissues. Six of the 
monoclonal antibodies were specific for HTLV-1 core protein and two were 
specific for HTL V-1 envelope proteins. The method used for immunostain­
ing was that described by Wiley et al (1986). 
5.3.5. Polymerase Chain Reaction Assay 
Total cellular DNA was extracted from formalin fixed paraffin embedded 
blocks of the spinal cord (Wright & Manos 1990) and amplified for the viral 
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gag gene. Details of methodology are presented in Appendix L. For 
comparison, a positive control HTL V-I infected cell line (SLB-1), a negative 
control non-infected human T-cell line (HVT 78), liver and lymph node 
tissue from a seropositive case of non-Hodgkins lymphoma and muscle from 
a seropositive case of polymyositis were similarly tested. 
5.3.6. In-situ Hybridization Studies 
These studies were performed according to the methods of Wiley et al 
(1986), except that instead of labelling the probe with 35s labelled
nucleotides, a digoxigenin label was employed. In brief, a 1.2 Kb HTLV-I 
tax sequence and a comparably sized pBR plasmid sequence were labelled 
by random primed incorporation of digoxigenin-labelled deoxyuridine­
triphosphate according to the Genius kit protocol (Boehringer Mannheim 
Biochemicals, Indianapolis, In, USA). The average length of the digoxigenin 
labelled probes is approximately 750 bases. Hybridization was performed 
for 18 hours at 37°C. The slides were extensively washed as per kit 
protocol, then developed with an immunocytochemical reaction using sheep 
anti-digoxigenin antisera. 
5.4.RESULTS 
5.4.1. Light Microscopy Studies 
Sections from the cervical, thoracic and lumbar levels of the spinal cord 
demonstrated mild meningeal chronic inflammation. Chronic perivascular 
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and parenchymal inflammation was noted in all levels of the cord but was 
most severe within the thoracic level (plates 5.1-5.3). Inflammation was 
restricted mostly to the white matter tracts in the lateral and posterior 
columns. Demyelination and axonal loss were noted in the inflamed regions. 
Bodian silver stains and immunocytochemical stains for neurofilament 
proteins demonstrated dystrophic dilatations of axonal processes. The 
GF AP stain demonstrated moderate gliosis in the inflamed areas. 
Immunohistochemical studies for the MHC antigen {32 microglobulin 
intensely labelled endothelial cells and infiltrating inflammatory cells. 
Occasional glial cells and Schwann cells also showed staining. However, no 
neuron expressed MHC class I antigen. Comparably prepared normal spinal 
cord sections showed no staining for this antigen. , Expression of class II 
antigen was restricted to inflammatory cells. 
5.4.2. Lymphocyte Marker Studies 
The inflammatory infiltrates consisted predominantly of CD8 positive cells 
and fewer CD4 positive cells. Scattered monocyte/macrophages and B-cells 
were also seen. 
5.4.3. Electron Microscopy Studies 
Thick sections of plastic embedded spinal cord tissue from the thoracic level 
demonstrated chronic perivascular inflammation as seen with the paraffin 
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sections. Cell membranes were poorly preserved and no viral particles could 
be identified. 
5.4.4. Viral Protein Detection Studies 
Immunocytochemical studies of paraffin embedded spinal cord sections for 
HTLV-I antigen were negative. Concurrently run preparations of 
equivalently processed paraffin embedded HTL V-I infected cell lines 
demonstrated abundant HTL V-1 antigens. 
5.4.5. Polymerase Chain Reaction Assays 
The PCR data, shown in Fig. 5.1, indicated that HTLV-I proviral DNA was 
detectable in DNA extracted from all 3 levels of the spinal cord. The 
amount of HTLV-I DNA in the thoracic cord was ·approximately 3-4 fold 
higher than in the cervical or lumbar cord sections. The signal obtained 
from these latter two areas of the cord were at the virtual limits of 
detectability by this method. It thus appears that the thoracic cord, which 
exhibits the most significant pathologic alteration, also harbours the 
highest amount of HTLV-1 DNA.
5.4.6. In-situ Hybridization Studies 
In an attempt to localise the cellular distribution of HTL V-I proviral DNA 
we performed in-situ hybridization of spinal cord sections from all 3 levels 
examined by PCR. Using the digoxigenin label probe, no hybridization was 
detected in any of these sections. 
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5.5. DISCUSSION
This patient almost certainly acquired his infection from the blood transfusion as 
there were no other risk factors. The short latent period before symptoms is a well 
recognised observation when transmission is via blood and blood products (Iwasaki 
1990; Gout et al. 1990). 
The pathological findings in the patient were similar to those described both before 
(Montgomery et al. 1964; Mani et al. 1969) and after (Akizuki et al. 1988; Piccardo 
et al. 1988; Iwasaki 1990) the association of TSP with HTLV-1 was established. It 
is salutary to note that Mani et al postulated a role for a slow virus as long ago as 
1969. The main histological finding in HAM/TSP as seen in the patient was 
mononuclear infiltrates in perivascular areas especially within the lateral and 
posterior white matter tracts. Myelin pallor and axonal loss Were noted in the same 
regions. All the changes were most prominent in the thoracic cord. 
The pathogenesis of HAM/TSP remains unclear. Some of the problems met with 
in the study of the pathogenesis include paucity of autopsy material, absence of a 
suitable animal model and difficulty in infecting cells of neural origin in vitro 
(Watabe et al. 1989). 
Evidence for direct viral infection is scanty. Liberski et al (1988) demonstrated 
viral-like particles on electron microscopy in spinal cord tissue. Due to suboptimal 
preservation the type of cells showing these particles was not identified. However, 
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neither we nor others (Wayne Moore et al. 1989; Power et al. 1991), saw particles 
resembling HTLV-1 on electron microscopy. 
Several workers (Iwasaki 1990; Piccardo et al. 1988; Cruickshank et al. 1989), 
including ourselves have failed to detect viral antigen in spinal cord tissue. This 
may in part be due to delay in performing the autopsy as well as formalin fixation. 
Wayne Moore et al (1989) demonstrated HTLV-1 p19 core protein in cells in the 
perivascular regions as well as in probable glial cells in the parenchyma. This 
observation is complicated by the fact that the antibody used by them cross reacted 
with normal tissue. 
The demonstration of proviral DNA in the spinal cord of the patient suggests that 
HTL V-1 may be directly involved in the disease process. The PCR assay showed 
a quantitatively greater signal in the thoracic cord than in the lumbar or cervical 
cord. This reflected the difference in the histopathology of these regions and 
further suggests that the cervical and lumbar cord are directly involved in the· 
disease process and not merely showing changes secondary to primary thoracic 
disease. The multilevel positivity contrasts with the finding by Power et al (1991) 
who could amplify the HTLV-1 gag gene from the cervical cord only. 
Unfortunately, the in-situ hybridization studies were unsuccessful in localizing the 
cells of origin of the proviral DNA detected by PCR. The signal intensity by PCR 
was quite low and extrapolating from studies of muscle in HTL V-1 seropositive 
patients, the signal in HAM/TSP spinal cords may be below the detectable limits 
of digoxigenin labelled probes. 
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It could be argued that the sources of the amplification product would include 
intraluminal monocytes and lymphocytes. However, these were scanty in the 
sections used for PCR and the signal was greatest in the thoracic cord which 
showed the maximal changes. Also Kira et al (1992) compared PCR results in 
HAM/TSP cords and A TLL infiltrated neural tissues. They found greater amounts 
of proviral DNA in HAM/TSP samples than the A TLL samples although the extent 
of mononuclear cell infiltration was far less in the HAM/TSP samples than the 
A TLL sample. This observation provides additional support for possible direct 
neurotoxicity of HTLV-1. 
There are two further pieces of evidence suggesting direct viral infection of the 
spinal cord. Firstly, the persistence of HTL V-I specific IgM antibodies in the CSF 
(McLean et al. 1989; Jacobson et al. 1990a) indicate ongoing viral replication and 
the production of new viral antigens. Secondly, our lymphocyte studies showed a 
predominant CD8 + infiltrate. These CD8 + cells may represent a similar subset 
to the circulating CD8+ cytotoxic T lymphocytes specific for HTLV-I pX in patients 
with HTLV-I neurological disease as noted by Jacobson et al (1990b) and may be 
homing in on specific viral proteins within the spinal cord. 
In contrast to the difficulty of demonstrating clear cut direct viral infection there 
is growing evidence of immune mediated neural damage as first suggested by 
Dalgleish et al (1988). The histological findings have been compared to those seen 
in recognised situations of acute disseminated encephalomyelitis (Iwasaki 1990). 
The finding of activated T-cells with polyclonal gammopathy (Mori et al. 1988), 
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antigen specific oligoclonal bands in the CSF (Ceroni et al. 1988), increased 
expression of interleukin-2 receptor molecules (Jacobson et al. 1990a), increased 
levels of interleukin-6 in CSF (Nishimoto et al. 1987) and genetic restriction (Usuku 
et al 1990; Jacobson et al 1990b) provide further support for an immune based 
pathogenesis. 
5.6 CONCLUSION 
The findings in this study suggest that HTLV-I may be directly involved in the 
disease process and that the sites of action of the virus may be more proximal than 
previously believed. However, the importance of immune mediated damage should 
not be underplayed. Genetic susceptibility (and hence immune response) would 




LEGEND TO FIG. 5.1: Upper panel shows normalised HTLV-1 "gag" PCR products. Lower panel contains normalised glycer­
aldehyde 3 phosphate dehydrogenase PCR products. Lanes 1-3: HTLV-1 infected SLB-1 cellular DNA at 0.1 ng, respectively. 
Negative controls: no template (water) (lane 4) and paraffin embedded_ HUT-78 T cells (lane 6). Positive controls (all DNA 
extracted from HTLV-1 paraffin embedded cell line or patient-derived tissues): SLB-1 T cells (lane 5), muscle from HTLV-1 
seropositive patient with myopathy (lane 7); liver (lane 8) and lymph node (lane 9) from HTLV-1 seropositive patient with non­
Hodgkins lymphoma. Spinal cord specimens from HAM/TSP patient (DNA extracted from paraffin embedded tissue): cervical 




HTLV-1 AND PERIPHERAL NEUROPATHY: 
A CLINICO-PATHOLOGIC STUDY 
6.1 INTRODUCTION 
Although TSP is primarily a spinal cord disorder, peripheral nerve dysfunction 
(PND) has been noted in various studies. The frequency of PND reported has 
varied from negligible to 32% (Montgomery et al. 1964; Barkhaus & Morgan 1988; 
Ludolph et al. 1988). The changes observed include distal wasting, stocking type 
peripheral sensory loss and absent ankle jerks. 
Since the demonstration of antibodies to HTLV-I in patients with TSP, most 
reports have concentrated on multimodality evoked response studies and have 
shown abnormalities in the central pathways (Kakigi et al. 1988; Cruickshank et al. 
1989). However, Cruickshank et al (1989) noted absent ankle jerks in 3 of their 21 
patients. Arimura et al (1987) did undertake peripheral nerve conduction studies 
in 6 patients but found few abnormalities. Bhagavati et al (1988) noted peripheral 
nerve electrophysiological abnormalities in 6 of 12 patients. 
We have found clinical evidence of PND in 23% of our patients and 
electrophysiological evidence in approximately 58% (Chapter 3). Of the patients 
with evidence of PND, 6 underwent sural nerve biopsies. The histopathological 
findings are presented. 
6.2 METHODS 
6.2.1. Light Microscopy Studies 
6.2.2. Electron Microscopy Studies 
6.2.3. Viral Protein Detection Studies 
6.2.4. In-situ Hybridization tests to detect proviral Nucleic Acids. 
6.2.5. Polymerase Chain Reaction Assays 
The above tests were done as described in Chapter 5. 
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In addition nerve fibre teasing and immunofluorescent studies for IgG, IgM, 
lgA were done. 
6.2.6. Morphometric Analysis 
One micrometre thick plastic sections were stained with p-phenylenediamine 
for standard morphometric analysis (Forcier et al. 1991). The fascicle image 
was projected onto a grid scored in 0.5 cm squares using a camera Lucida 
attachment. The area of each fascicle was determined by digitizing prints 
(242 x final magnification) using a Jandel digitization pad with Sigma scan 
software. Mean axonal diameters of each nerve were calculated by first 
multiplying the percent volume fraction of axons by the total fascicular area 
and dividing by the total number of myelinated fibres. The calculated mean 
axonal area was then used to calculate mean axonal diameters by assuming 
a circular axonal profile and calculating the equivalent diameters. To 
compare these data to published standards, similar values were derived from 
data published by Behse (1991). 
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6.3 RESULTS 
6.3.1. Light Microscopy Studies 
No inflammatory infiltrate was seen. 
6.3.2. Immunofluorescent Studies 
No deposit of IgG, lgM, IgA or complement was detected. 
6.3.3. Electron Microscopy 
The semi-thin sections of the six sural nerves are shown in Plate 1 (a-f). 
The ultrastructural findings were as follows: 
1. The nerves of patients 1,2,3 and 5 showed mild to moderate loss of
myelinated fibres. Several fibres demonstrated disproportionately thin 
myelin sheaths suggestive of remyelination. Patient� 1 and 2 showed occas­
ional clusters of regenerating axons as well as proliferated Schwann cell 
processes without axons. The unmyelinated fibres appeared normal. 
2. The biopsy from patient 4 showed severe loss of myelinated fibres, axonal
atrophy, occasional degenerating axons and groups of small myelinated 
fibres probably representing regenerating clusters. There was a normal 
complement of unmyelinated fibres. 
3. The sural nerve of patient 6 showed severe loss of both myelinated and
unmyelinated fibres. Numerous degenerating axons were present. Bungner 
bands were prominent. 
4. Endoneurial fibrosis was mild in nerves from patients 1,2,3 and 5 but
moderate to severe in nerves from patients 4 and 6. 
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No virus or virus-like particles were seen in any of the specimens. 
6.3.4. Teased Fibre Preparations 
The findings of the teased fibre studies are summarised in Table 6.1. They 
range from predominantly normal features e.g. case 2, to severe axonal 
changes e.g. case 6. Several fibres showed multiple features e.g. 
combinations of demyelination, remyelination and "globules". 
6.3.5. Morphometric Studies 
The derived average axonal diameters of the patients' nerves were similar 
(4.58 ±. 0.47: mean±. SD). Myelinated fibre number, number of fascicles, 
total fascicular area and myelinated fibre density are shown in Table 6.2. 
Myelinated fibre densities in all patients were below the normal range. 
6.3.6. Viral Protein Detection Studies 
No viral products were detected in the tissues examined. 
6.3.7. In Situ Hybridization Tests 
Viral nucleic acids were not demonstrated. 
6.3.8. Polymerase Chain Reaction Assays 
All samples tested negative for proviral DNA. 
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6.4 DISCUSSION 
One of the earliest detailed reports of histological changes in the peripheral 
nervous system was that by Said et al (1988), who found perineurial and 
perivascular inflammatory infiltrates, moderate axon loss, areas of demyelination 
and Wallerian degeneration in a biopsy of the superficial branch of the peroneal 
nerve. The changes were thus similar to those in the spinal cord and roots. 
Makazato et al (1989) found a decrease in the number of larger myelinated fibres, 
frequent denervated Schwann cell clusters but no inflammatory infiltrate in a small 
nerve biopsy. Sigumura et al (1990) reported on sural nerve pathology in three 
patients. Their biopsies showed segmental demyelination, remyelination and 
frequent globules. No inflammatory infiltrate was observed. They considered 
demyelination with globule formation to be characteristic of peripheral neuropathy 
in HAM/TSP. 
The sural nerve changes noted in the six patients of this study were similar to those 
described by Sigumura et al (1990). The morphometric studies gave results 
consistent with a normal reparative process, a decrease in myelinated fibres as well 
as a decrease in axonal diameters. The decreased axonal diameters may be 
explained by either preferential loss of larger myelinated fibres or axonal atrophy. 
Unlike Said et al (1988), others (Nakazato et al. 1989; Sigumura et al. 1990) 
including ourselves, have not been able to show any inflammatory infiltrates. A 
possible explanation may be the choice of nerve biopsied as Said et al (1988) 
biopsied a larger and more proximal nerve. 
63 
Other incidental causes of peripheral neuropathy were considered in our patients. 
However, all patients had symptoms of short duration; none were bedridden or 
critically ill and all had satisfactory nutritional status. None abused alcohol, nor 
had hepatic, respiratory or renal disease, underlying malignancy or diabetes 
mellitus. Apart from hereditary tendency to pressure palsy (Bradley et al. 1975), 
"globule formation" has not been properly documented in other neuropathies. We 
concur with Sigumura et al (1990) that the PND is part of HTL V-1 associated dis­
ease and not an unrelated abnormality. 
The pathpgenesis of PND in HAM/TSP remains unclear. Said et al (1988) point 
out that the lesions they noted in the peroneal nerve were similar to those in the 
central nervous system. This raises the possibility of similar pathogenic 
mechanisms. They also cite comparable changes in the inflammatory neuropathy 
associated with the human immunodeficiency virus (HIV), and other retroviruses. 
However, many cases of this type of inflammatory neuropathy may be due to 
another infection viz cytomegalovirus (Grafe & Wiley 1989). 
At the level of the biopsied site there was no evidence of direct HTL V-1 infection. 
A consideration is that changes seen in the distal end of the PNS (in this study, the 
sural nerve) are secondary to more proximal disease, e.g. in the roots which may 
show the same inflammatory process as in the cord (Montgomery et al. 1964 ). 
Multi-level studies of the peripheral nerves at necropsy may shed light on the 
pathogenesis of PND in HAM/TSP. 
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TABLE 6.1: RESULTS OF NERVE FIBRE TEASING 
Biopsied 
Patient Normal Demyelin/ Ovoids "Globules" 
No Remyelin 
(Series No) 
1 ( 1) 
2 (2) 




77 23 3 0 
88 11 4 0 
81 17 3 4 
25 60 36 10 
75 16 0 14 
13 0 86 1 










In a HTL V-I seroprevalence study in patients with neurological disease other than 
HAM/TSP, Mora et al (1988) found that all 7 Jamaican patients with isolated adult 
onset polymyositis (AOP) tested positive. Their extended studies (Moran et al. 
1989) noted that 11 of 13 (85%) patients of AOP had antibodies to HTLV-I. Most 
subsequent reports of antibody positive polymyositis have been in patients with 
associated HAM/TSP (Goudreau et al. 1988; Tarras et al. 1989; Francis & Hughes 
1989, Evans et al. 1989). Polymyositis with dual HTLV-I and HIV infection has 
been reported in two further cases (Wiley et al. 1989; McArthur et al. 1990), one 
of whom had an associated myelopathy. 
During the course of the HAM/TSP study 3 patients with disproportionate proximal 
weakness were identified and studied in greater detail. For comparison 11 other 
patients with isolated AOP were tested for HTLV-I antibodies. 
7.2. MATERIALS AND METHODS 
Muscle biopsy specimens were taken under local anaesthesia from either the biceps, 
deltoid or quadriceps and subjected to the following tests: 
1. Routine staining of fresh and paraffin embedded sections with
haematoxylin and eosin, A TPase and NADH.
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2. Specimens were fixed in 3% phosphate buffered glutaraldehyde and
processed for electron microscopy according to standard techniques.
3. Viral protein detection studies: See chapter 5 for methodological
details.
4. In-situ hybridization was performed according to the methods of
Wiley et al (1986). See chapter 5 for details.
5. Polymerase chain reaction assays were done on DNA extracted from
paraffin embedded sections and processed according to the PCR
protocols (Wright & Manos 1990). See chapter 5 for details.
7.3. CASE HISTORIES 
7.3.1. Case 1 (CM - Series No 43)
This 27 year old Black woman was first examined in April 1989. Apart from 
evidence of a myelopathy she had disproportionate proximal weakness 
(MRC grade 4/5) of all four limbs. Electromyography (EMG) of the 
proximal muscles ( deltoid, biceps, quadriceps) showed features of a 
'myopathic' disorder. Following a muscle biopsy, prednisone (60 mgs/day) 
was administered. No definite improvement was noted over a 6 month 
period when a second muscle biopsy was performed. 
7.3.2. Case 2 (TN - series no 47) 
This 29 year old Black woman presented with a six week history of lumbar 
backache, numbness of the legs and progressive weakness of all 4 limbs. 
She had evidence of a myelopathy with a sensory level at T4 and 
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disproportionate proximal weakness of arms and legs. There was no 
weakness of the neck or bulbar muscles. EMG showed features similar to 
case 1. 
7.3.3.Case 3 (HN - Series no 86) 
This 28 year old Black woman presented with a two year history of pain in 
the legs, difficulty in walking and urinary urgency. Apart from her 
myelopathy she had marked proximal weakness of upper and lower limbs. 
There was no neck or bulbar muscle weakness. 
7.4.RESULTS 
The relevant routine blood tests of the 3 patients are summarised in Table 7.1. In 
the isolated AOP group (i.e. without HAM/TSP) there were5 males and 6 females. 
Of these only one patient exhibited antibodies to HTL V-1. This patient was a 28 
year old Black woman who gave a 2 month history of dysphagia, dysarthria, nasal 
regurgitation and proximal limb weakness. She had mouth ulcers as well. 
Examination showed facial, jaw, neck and proximal limb weakness. The upper 
limbs were weaker than the lower limbs. Sensation was intact. Besides the 
expected raised creatinine kinase (CK) and a positive muscle biopsy, she 
demonstrated antinuclear antibodies - speckled pattern; titre 1:800. She was started 
on prednisone (60 mgs/day) and began showing improvement after 3 weeks of 
treatment. 
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All the muscle biopsy specimens showed mononuclear inflammatory infiltrates 
within the fascicles and degenerating muscle fibres (Plate 7.1 a,b ). The biopsies 
from the HAM/TSP patients also showed varying numbers of small fibres, 
angulated fibres, fibre type grouping and group atrophy - all features suggesting 
associated neurogenic changes. None of the biopsies showed a vasculitis. 
The viral protein studies, the in-situ hybridization tests and the polymerase chain 
reaction assays all gave negative results. 
7.5. DISCUSSION 
AOP is characterised by subacute to chronic progressive weakness of proximal 
muscles including the neck and often the bulbar muscles. Cardiac involvement may 
occur in up to 40% of patients. The CK is nearly always 'raised several fold, the 
EMG demonstrates characteristic features and a representative muscle biopsy is 
diagnostic. Response to steroids, even if only initial or partial, is noted in most 
patients. 
Apart from a sub-group of cases associated with systemic auto-immune disorders 
(Dalakas 1991), the aetiology of AOP has remained elusive. Reports linking the 
disorder with viruses such as the picornaviruses (Bowles et al. 1987; Yousef et al. 
1990) have not been conclusively proven. Animal (Dalakas et al. 1987) and human 
(Mora et al. 1988; Dalakas & Pezeshkpour 1988) retroviruses are the first group of 
viruses that have been consistently associated with polymyositis in adults. In 
HIV-positive patients, the polymyositis may be the first sign of infection or may be 
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seen with fully developed AIDS. However, attempts to demonstrate direct viral 
infection of the muscle fibre by HIV have not been successful (Dalakas 1991). 
HTLV-I related muscle disease has been seen in association with HAM/TSP or in 
patients with dual HIV /HTL V-I infection. In the 3 cases described here, all had 
associated HAM/TSP and the one patient given steroids showed no response. In 
the comparison group of 11 isolated AOP, only one had HTLV-I antibodies. Of 
interest, this patient had a significantly raised titre of antinuclear antibodies and 
showed the expected steroid responsiveness. Attempts to demonstrate the virus, 
proviral DNA and viral proteins in the patients have been unsuccessful. This may 
be due to sampling as the direct infection may be patchy. On the other hand the 
finding may be truly representative and suggests that HTL V-I triggers off an 
immune mediated cytotoxic damage similar to that postulated for AOP (Dalakas 
1991). 
7.6 CONCLUSION 
This study demonstrated that HTLV-1 may be associated with an inflammatory 
myopathy. However, unlike the Jamaican experience an unequivocal association 




DUAL HTLV-1 AND HIV-1 INFECTION: 




The modes of transmission of HTLV-I and HIV are similar. With the spread of 
HIV to previously endemic HTLV-I regions, it was not surprising that reports of 
dual HTL V-I and HIV infection soon followed. Initial studies also noted a high 
seroprevalence of HTLV-I amongst intravenous drug users (Gradilone et al 1986), 
but such cases were later shown to be due to HTLV-II infection (Lee et al. 1989). 
True dual infection has been reported in patients from the USA (Palmar et al. 
1985; Harper et al. 1986; Kanner et al. 1987; Chang et al. 1988; Wiley et al. 1989; 
McArthur et al. 1990; Berger et al. 1991), Zaire (Getchell et al. 1987), the 
Caribbean (Bartholomew et al. 1987a), Brazil (Cortes et al. 1989) and West Africa 
(Ramiandrisoa et al. 1991). In the Wentworth Hospital HAM/TSP study, six 
patients were seropositive for both HTLV-I and HIV. Their clinical and laboratory 
profiles are presented and the probable pathogenesis of their neurological disorder 
discussed. 
8.2 METHODS 
These patients underwent the same range of investigations as the other HAM/TSP 
cases. 
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8.3 CASE HISTORIES 
8.3.1. Case 1 (NN - Series no 35) 
A 17 year old Black woman presented to the Neurology Unit in March 1988 
with progressive weakness of the legs. After investigation a diagnosis of an 
inflammatory myelopathy of uncertain cause was made, the patient 
commenced on antituberculous therapy and discharged. 
The patient was lost to follow up until January 1989 when she was 
readmitted for assessment. She had not continued her antituberculous drugs 
and felt that her neurological deficit was stable. Examination revealed a 
spastic quadriparesis. The tendon reflexes were brisk, both plantar 
responses were extensor and abdominal reflexes absent. The mental state, 
cranial nerves, coordination and sphincter function were normal. The rest 
of the clinical examination was normal. Specifically there was no skin rash, 
lymphadenopathy, hepatosplenomegaly, arthritis or evidence of heart or lung 
disease. 
Investigations done during her most recent admission are summarised in 
Table 8.1. CSF bacterial (including mycobacterial) and fungal cultures were 
negative and the cryptococcal antigen was not detected. In vitro T cell 
function showed slightly reduced response to phytohaemagglutinin stim­
ulation but marked spontaneous lymphocyte transformation. The stimu­
lation index was 5.5 (normal > 100). Delayed hypersensitivity was evaluated 
using the multitest CMI kit (Institut Merieux). The patient demonstrated 
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total anergy to all seven antigens tested - tetanus, diphtheria, streptococcus 
group C, tuberculin, candida, trichophyton and proteus. Following discharge 
she was lost to follow up. 
8.3.2 Case 2 (FS - Series no 41) 
This 19 year old Black woman presented in 1987 with acute onset of pain 
in the legs with subsequent weakness progressing over a period of three days 
to total paralysis. She denied any preceding influenza-like illness, trauma, 
backache or other neurological symptoms. 
Her mental state, cranial nerves and upper limbs were normal. She had a 
flaccid paraplegia and was incontinent of urine. The tendon jerks at the 
knees were brisk but absent at the ankles. The plantar responses were 
equivocal. Apart from mild impairment of joint position sense, sensation 
was intact. The rest of the physical examination was normal. 
The CSF cryptococcal antigen latex agglutination and the cysticercus ELISA 
tests were negative. Rectal snip demonstrated ova of S. mansoni. The 
patient was treated with Praziquantel and steroids for presumed spinal 
schistosorniasis but showed no response. Following discharge she did not 
return for follow up. 
80 
8.3.3. Case 3 (ZG - Series no 65) 
This 25 year old Black woman presented with a 10 month history of urinary 
urgency, urge incontinence and progressive weakness of her legs. She 
denied any other neurological symptoms. She was treated twice in the past 
for pelvic inflammatory disease. 
On examination she was pale and pyrexial. The latter was due to a urinary 
tract infection and settled on antibiotic treatment. There was no 
visceromegaly. The mental state and cranial nerves were normal. In the 
upper limbs the distal power was grade 4/5. There was grade 1 - 2 power 
in the lower limbs. The tendon jerks in the upper limbs and knees were 
brisk but were absent at the ankles. The plantar responses were equivocal. 
She had patchy impairment to pin prick and touch 'to the T6 dermatome. 
Joint position and vibration sense were intact. 
She was discharged following an improvement in her general condition. She 
failed to return for review. 
8.3.4. Case 4 (MM - Series no 87) 
This 34 year old Black man developed pain and paraesthesia in his feet, and 
lumbar backache in July 1990. A month later he developed weakness of the 
legs which gradually progressed so that he had become wheelchair bound by 
February 1991. Sphincter dysfunction followed 3 months later. 
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Examination revealed a normal mental state and cranial nerves. There was 
mild wasting of the small muscles of the hands but power was normal. The 
power in legs was graded as 3-4/5 proximally and 0/5 at the ankles and toes. 
The knee tendon reflexes were brisk but the other jerks were normal. The 
plantar responses were extensor and the abdominal reflexes absent. Pin 
prick and light touch was impaired in a graded fashion below the knees. 
Joint position sense was defective at the toes and vibration sense impaired 
up to the hips. 
8.3.5.Case 5 (BN - Series no 82) 
This 40 year old Black man presented with a one month history of 
progressive weakness of the legs, numbness and sphincter dysfunction. He 
had received blood transfusion 3 years previously following a stab chest. 
Examination revealed generalised lymphadenopathy, 2-3 cm in diameter, 
firm mobile and non tender. The only other abnormality was a spastic 
paraparesis (grade 4/5) with a Tl2 sensory level. The tendon reflexes in the 
legs were brisk and the plantar responses were extensor. 
Biopsy of an axillary lymph node showed cortical and paracortical 
hyperplasia, folliculolysis and smus histiocytosis. Immunoblasts were 
numerous and plasma cells were identified in the medulla. 
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8.3.6. Case 6 (SM - Series no 67) 
This 26 year old Black man presented with a 2 month history of headache, 
backache and lower limb weakness. He complained of numbness in the legs 
but had no sphincter disturbance. He had conjunctivitis and seborrhoeic 
dermatitis. There was no lymphadenopathy. The mental state and cranial 
nerves were normal. He had mild distal weakness of the arms. In the legs 
the power was graded as 2/3 proximally and 0/5 distally. Only the biceps 
and knee tendon reflexes were elicited. The abdominal reflexes were absent 
and both plantar responses were extensor. Sensation to all modalities was 
impaired up to the calves. 
The relevant blood tests, the CSF profiles and lymphocyte marker studies of the 
above cases are summarised in Tables 8.1, 8.2 and 8.3 respectively. 
8.4. DISCUSSION 
In HAM/TSP, besides the myelopathy, the mental state is normal, the cranial 
nerves are rarely affected, CSF pleocytosis is common and some patients may 
respond to steroids. Myelopathy in HIV infection may occasionally occur at 
seroconversion (Denning et al. 1987; unpublished personal data). In these cases the 
clinical picture is that of an acute transverse myelitis and spontaneous improvement 
may be noted. Better recognised and more frequent is the vacuolar myelopathy 
(VM) seen in the advanced stages of HIV infection (Petito et al. 1985; Goldstick 
et al. 1985). VM is commonly seen in association with dementia and is seldom the 
sole neurological manifestation of HIV disease. However, subclinical spinal cord 
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dysfunction has been described in latent HIV infection (Jakobsen et al. 1989). 
CSF pleocytosis is not a feature. 
The pathogenesis of HAM/TSP is unclear and has been discussed in chapter 5. 
The pathogenesis of VM is equally uncertain. On the one hand there is evidence 
suggesting direct viral infection (Maier et al. 1989) but on the other Rosenblum et 
al (1989) found a poor correlation between the presence of productive infection 
within the cord and VM. 
Patients 1 - 4 had a myelopathy as the sole clinical presentation. None had a 
history or evidence of an AIDS defining illness. The mental state was normal but 
it must be noted that formal neuropsychological testing was not done. The 
lymphocytes of patient 1 showed evidence of spontaneous proliferation and a 
decreased stimulation index. All the features described above would suggest that 
HTL V-I was responsible for these 4 patients' disease. However, of note is that the 
CD4/CD8 ratios were low and the absolute CD4 counts were in the low normal 
range in the patients tested. 
Patient 5 had no other neurological manifestations nor a history of opportunistic 
infection. However, he had generalised lymphadenopathy and biopsy showed 
features of Primary Generalised Lymphadenopathy (PGL) as seen in HIV infection. 
His CD4 count was raised and the CD4/CD8 ratio was normal. His neurological 
problem was probably due to HAM/TSP. 
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Patient 6 is more problematical and his entire clinical presentation could reflect 
HIV seroconversion (Denning et al. 1987). Co-infection of HIV and HTLV-1
provides an example of virus - virus interaction. There is evidence to suggest that 
HTLV-1 enhances HIV infection. De Rossi et al (1986) demonstrated increased 
HIV antigen when lymphocytes were co-infected than when infected with HIV 
alone. Zack et al (1988) noted that HTLV-1 virions may exert their effect before 
or after the cells were infected with HIV-1. In vitro studies have also shown that 
the HTLV-1 transactivator protein tat-1 can activate the long terminal repeats 
(LTR) of HIV (Siekevitz et al. 1987). Bartholomew et al (1987b) provide clinical 
evidence for more rapid progression to AIDS in co-infected individuals than in 
those infected with HIV alone. 
Of further interest in the present study is that the reversal of the CD4/CD8 ratios 
in two of the three patients tested is in part due to absolute increase in CDS counts. 
Early increase in CDS counts have been noted in HIV infection and may represent 
an attempt on the part of the immune system to resist HIV or other pathogens 
(Cooper et al. 1988; Giorgi & Detels 1989). There is evidence that HTLV-1 too 
can cause CDS proliferation. Harper et al (1988) found that HTLV-I integration 
of lymphocytes from their dually infected patient was predominantly clonal. The 
cell lines established by Ehrlich et al (1989) were initially polyclonal but later grew 
out the same two clones. Their patient also developed nasopharyngeal and 
pulmonary lymphoid nodules which regressed on steroids and cytotoxic therapy. It 
could be speculated that destruction of HIV infected CD4 cells may allow 
unchecked proliferation of CD8 and HTLV-I infected cells. 
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8.5. CONCLUSION
With the advent of the HIV epidemic in Southern Africa more cases of dual 









The worldwide prevalence of HTL V-1 infection demonstrates marked geographical 
variation (Table 9.1), ranging from 0% in China to 12% in Japan and 26% in the 
Melanesia Islands. HTLV-I is also common in Africa (Table 9.2). However, the 
reliability of some of these estimates is questionable. Gross national estimates may 
obscure foci of high prevalence. For example the 0.025% seroprevalence in the 
USA conceals the endemic focus in the South East region of that country. 
Furthermore, the serological tests have in some hands lacked specificity. The 
previously reported high seropositivity (37.7%) among the Ethiopian Jews who 
emigrated to Israel have been shown to be incorrect (Karpas et al. 1986). The 
initial controversy of the Melanesian studies has been resolved by the occurrence 
of HAM/TSP (Ajdukiewicz et al. 1989) and the isolation of HTLV-I from that 
region (Yanagihara et al. 1990). Similarly in Africa Ramiandrisoa et al. (1991) 
demonstrated lower seroprevalence rates in the Ivory Coast ( .18% ), Senegal (0.3% ), 
and Burkina Faso (0.8%) than previously reported (De The' et al. 1985). 
Seroprevalence of HTLV-I infection in South Africa varies from 0% amongst blood 
donors of all races to 5.2% amongst Black female staff at the Kruger National Park 
(Table 9.3). In order to obtain more information about the magnitude of HTLV-I 
infection in the Natal region, and to evaluate the risk factors for acquiring the virus, 
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a seroprevalence study was undertaken in the Ngwelezane district of Natal/Kwa 
Zulu. For comparison, coded samples were tested for HIV 1/2 as well. 
9.2 METHODS 
The Ngwelezane district was chosen for the survey because (a) cases of HAM/TSP 
had been seen in this area, (b) the local hospital was conveniently located to act as 
a base, (c) the area was within easy reach of Durban. Apparently healthy 
individuals over the age of 15 years were recruited from the Ngwelezane township 
and nearby shopping complexes. The purpose of the study was explained to groups 
of individuals. Those who volunteered answered a brief questionnaire (appendix L) 
and donated a sample of blood. 
Blood was collected in a pre-chilled tube and transported to the laboratory in an 
ice box within 5 hours. Following separation the serum samples were stored at 
-20°C. Testing was done within 2 months of sample collection. The test kits were
the same as those described in Chapter 3. In view of the difficulty in distinguishing 
HTLV-I from HTLV-11 on serological tests all Western Blot HTLV-I positive 
results were tested for HTL V-11 using the Coulter Select-HTL V test kit. 
The association between HTL V-I infection and the risk factors of age, gender, age 
at first sexual experience, blood transfusion and the number of units transfused, 
number of sexual partners, marital status, occupation and scarifications were 
assessed using the Chi square (or Fisher's exact) or t-test. 
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9.3 RESULTS
A total of 1018 individuals, 490 males (48.12%) and 528 females (51.9%), 
participated in this study. The age range was 15 - 82 years with a mean of 31.5 (SD 
.±. 12.7) years. Most subjects were unemployed (56.6%), 62.8% were single, 68.7% 
had evidence of scarification and 13.1 % had received blood transfusion in the past. 
Sixty eight persons declined to provide information about their sexual behaviour 
and a further 10 indicated that they had never been sexually active. Of the 
remainder, the mean age at first sexual experience was 17.9 (SD.±. 2.7) years and 
the mean number of sexual partners was 1.5 (SD .±. 1.07). 
A total of 26 (2.6%) (95% confidence interval 1.62 - 3.58) sera, of which 16 were 
from males, tested positive for anti HTL V-1 antibodies. A further two had 
indeterminate results on Western Blot and for the purposes of analysis were 
regarded as negative. Another serum demonstrated antibodies to HTLV-11. 
Of all the risk factors assessed, only age showed a significant correlation (p < 0.05; 
and figure 9.1). The age-related prevalence rates are summarised in Table 9.4. 
Thirty six (3.5%) sera tested positive for anti HIV-1 antibodies. No sample tested 
positive for antibodies to HIV-2. The relative risk of co-infection with HIV-1 given 
that the individual was HTLV-1 positive was 3.46 (95% confidence interval 
1. 135 - 10.526).
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9.4 DISCUSSION
This study showed the prevalence of HTLV-1 infection in the Ngwelezane district 
to be 2.6%. More males than females were seropositive. The most likely 
explanation is that the sample contained more older men than older women and 
there is an age related increase in HTL V-1 seropositivity. 
The seropositivity increased with age to 6.1 % in those over 55 years of age. This 
finding is consistent with the world-wide experience. The rise with age may relate 
to the age at exposure to the virus and the time to seroconversion. 
The modes of transmission of HTLV-1 are from mother to child (predominantly 
through breast milk), through sexual intercourse, blood transfusion and intravenous 
drug abuse (Blattner 1989). Obvious parenteral spread C'an be excluded in the 
study sample. Intravenous drug abuse is not practised and neither blood transfusion 
nor scarification showed a significant association with HTLV-1 infection. However, 
the multiply transfused individual will always be at risk. 
The problem of mother to child spread is more difficult to evaluate because of the 
question of latent, seronegative HTLV-1 infection. About 20% of children of 
seropositive mothers convert, usually between 12 and 24 months of age (Hino et al. 
1985). The seroprevalence rate in children then remains the same until the teenage 
years (Kajiyama et al. 1986). An explanation proposed for this observation is that 
some children of seropositive mothers may seroconvert only decades later as 
suggested by experimental (Yamada et al. 1991) and some human studies (Ehrlich 
I 
94 
& Poeisz 1988; Saito et al. 1989). On the other hand, studies by another Japanese 
group (Nakashima et al. 1990) and Pate et al (1991) failed to confirm a sero­
negative HTLV-1 carrier state in children. In a separate paediatric study of 561 
healthy Zulu children under the age of 16 years I found no cases of HTL V-1 
seropositivity (unpublished data). In another small unpublished study 4 offspring 
of 3 women with HAM/TSP were tested for HTLV-1 seropositivity. Only one, a 
2 year old, was positive whilst her 10 year old sibling was negative. The 
interpretation of this finding is made difficult by the practice of multiple sexual 
partners as the time of maternal acquisition of infection and hence spread to her 
offspring could be variable. Another factor to consider is that, whilst breast feeding 
is almost universally practised, economic needs often necessitate premature 
weaning. 
The main mode of transmission in our subjects remains to be defined. However, 
the relative risk of 3.46 for co-infection with HIV-1 would suggest that sexual 
transmission is important. 
9.5 CONCLUSION
This seroprevalence study, together with the cases of HAM/TSP confirm the Natal 
region to be an endemic HTLV-1 area. 








CONCLUSIONS AND FUTURE HTLV-1 
RESEARCH 
10.1 PATHOGENESIS OF HAM/TSP 
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Whilst the association between HAM/TSP and HTL V-1 is well established, the 
pathogenesis remains elusive. The current evidence would suggest that a co-factor 
is necessary for the development of the myelopathy. This co-factor may be a 
genetic predisposition. MHC restriction has been demonstrated in this regard 
(Usuku et al 1990; Jacobson et al 1990b ). The paucity of post mortem spinal cord 
tissue has also hampered progress in determining the pathogenesis of HAM/TSP. 
The presence of gag proviral DNA in the spinal cord has been demonstrated 
(Chapter 5). This study, however, does not define the cell type harbouring the 
proviral DNA. The use of in-situ PCR (Bagasra et al 1992) may prove informative 
in this regard. 
There is lack of a suitable animal model. Although experimental animals can be 
easily infected with HTLV-1, the virus does not produce disease in them. Whether 
infection of the SCID-HU mice results in disease remains to be seen. 
10.2 CLINICAL ASPECTS OF HAM/TSP 
10.2.1. Diagnosis 
The diagnosis of HAM/TSP is straightforward. Of greater importance are 
cases resembling HAM/TSP but are antibody negative. These cases may 
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have a completely different aetiology or may in fact be true seronegative 
cases of HAM/TSP. Using PCR d'Auriol et al (1990) were able to detect 
proviral HTL V-I DNA in the PBLs of 18 out of 20 antibody negative cases. 
This observation requires further study. 
10.2.2. Management 
The successful treatment of HAM/TSP with immunosuppression and 
plasmapheresis (Osame et al 1987; Matsuo et al 1988) in Japanese patients 
has not been duplicated elsewhere. The French have tried Zidovudine 
without success (Gout et al. 1991). High dose methylprednisolone, too, 
showed little benefit (Duncan & Ridge 1990). A properly randomised 
double blind placebo controlled trial is required to objectively evaluate the 
different forms of therapy. 
10.3 EPIDEMIOLOGY 
Seroepidemiological studies have indicated that HTL V-I infection is widespread. 
Foci of infection have been noted in virtually every continent and the evidence 
suggests that HTL V-I is an ancient virus. Less certain is the major mode of spread 
in some of the areas. In Japan, however, screening blood donors has virtually 
eliminated spread by blood transfusion (Osame et al. 1990b ). Mother to child 
spread can be effectively prevented by prohibiting breast feeding but this would 
have serious implications for the infant in Third World countries. 
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10.4. HTLV-I AND OTHER NEUROLOGICAL DISEASE
There is no doubt that the demonstration of an association between HlLV-1 and 
neurological disease represents a major advance. It has sparked off the search for 
viruses in other unexplained neurological disorders. A retrovirus may yet be 
aetiologically linked to Multiple Sclerosis (Perron et al. 1991) despite the earlier 
controversy. 
10.5 FUTURE HTLV-I RESEARCH IN SOUTH AFRICA
As a follow up to this thesis the following HlLV-1 related projects are being 
planned: 
(1) The search for MHC restriction in our HAM/TSP using PCR
(2) Determining extent of intrafamilial spread of the virus using
serological tests and PCR
(3) The search for HlLV-1 proviral DNA in antibody negative cases of
non-compressive myelopathy
( 4) The setting up of a national register of HAM/TSP cases.
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APPENDIX A: MYELOPATHY PROTOCOL* 
BLOOD TESTS 
Full blood count 
Erythrocyte sedimentation rate 
Urea and electrolytes 
Liver function tests 
Serum protein electrophoresis 
Serum immunoglobulins 
Serum angiotensin converting enzyme 
Serum folate and Vitamin B 12 
Serological tests for syphilis 
Bilharzia! immunohaemagglutination test 
Cysticercosis ELISA 
Serological tests for mycoplasma 
Viral antibody studies: EBV, cytomegalovirus, herpes 
simplex, herpes zoster, measles, influenza HTLV-I and 
HIV 1/2 
STOOL AND URINE EXAMINATION AND RECTAL MUCOSAL BIOPSY 
For detection of bilharzia! ova 
127 
CEREBROSPINAL FLUID TESTS 
Cell count, protein, globulin, glucose concentration 
Bacterial (including mycobacterial) culture 
Serological tests for syphilis 
Antischistosomal ELISA 
Cysticercosis ELISA 
Cryptococcal antigen test 
Viral antibody studies: as per blood tests 
CSF lgG index 
Isoelectric focusing for IgG oligoclonal bands 
RADIOLOGICAL STUDIES 
Radiographs of chest and spine 
Conventional myelography followed by CT 
CT scan of the brain 
* not all tests done in every patient
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APPENDIX B: MRC POWER GRADING SYSTEM 
GRADE 0 No contraction 
1 Flicker or trace of contraction 
2 Active movement with gravity eliminated 
3 Active movement against gravity 
4 Active movement against gravity and resistance 
5 Normal power 
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APPENDIX C: METHODOLOGY FOR THE 
DETECTION OF lgG OLIGOCLONAL BANDS IN 
CSF 
PREPARATION OF GEL 
d-Sorbitol (3.6g) and 0.3g Agarose IEF were dissolved in 27 ml 10% aqueous
glycerol using a boiling water bath. The liquid gel was equilibrated in a water bath 
at 65°C. Two ml Pharrnalyte 3-10 and 0.5 ml Pharrnalyte 8-10.5 were then added 
to this, allowed to cool and then stored in a moist chamber at 4°C until use. 
ISOELECTRIC FOCUSING 
After the frame was removed the gel was placed on the cooling platten. Surface 
fluid was removed with a sheet of nitrocellulose membrane (NCM), which was then 
discarded. 
Paired serum and CSF samples were then applied and focused using a voltage of 
1200 and power of 20w for a total of lO00V-hrs. 
BLOTTING 
The gel was pre-blotted with another sheet of NCM which was also discarded. A 
third sheet of NCM was applied and overlayed with filter paper, several layers of 
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blotter and a glass slab on which was placed a weight of 1kg. Transfer of 
immunoglobulins from gel to NCM was allowed to proceed for 30 minutes. 
The NCM was then placed in 2% dried milk in saline for 30 minutes and then 
rinsed in tap water. Fifty ml of 0.2% milk in saline containing 50 µl goat anti­
human IgG Fe was added for 30 minutes. The NCM was then washed in several 
changes of tap water. The second antibody (50 µl horse-radish peroxidase 
conjugated rabbit antigoat serum) was allowed to react with the NCM for a further 
30 minutes. The NCM was washed once more and developed with a solution of 20 
mg ethylamino carbazole dissolved in 20 ml methanol and added to 100 ml 0.02M 
acetate buffer (pH 5.1), containing 100 µl of hydrogen peroxide. The colour was 
allowed to develop for approximately 20 minutes. The NCM was washed and dried. 
INTERPRETATION 
A result was positive if there were two or more bands present in the CSF and not 






APPENDIX E: RESULTS OF IgG INDEX AND OLIGOCLONAL BANDS 
Pt. No CSF Se CSF Se lgG Oligo-
Albumin Albumin IgG IgG Index clonal 
Bands 
2 0.48 31.5 0.25 19.6 0.84 ND 
3 0.22 38.5 0.31 34.5 1.59 p 
4 0.15 43.0 0.07 13.8 1.46 ND 
5 0.70 39.7 0.02 22.1 0.04 ND 
6 0.56 40.2 0.03 29.1 0.07 N 
7 0.09 25.3 0.12 37.9 0.80 ND 
10 0.09 40.0 0.10 19.8 2.24 ND 
11 0.12 36.9 0.05 32.5 0.43 ND 
13 0.35 40.0 0.06 12.9 0.53 N 
14 0.20 33.0 0.17 19.5 1.48 p 
15 0.26 45.8 0.18 24.7 1.28 ND 
16 0.13 40.0 0.08 26.4 0.88 ND 
17 0.26 41.5 0.55 24.9 3.60 ND 
18 0.08 42.0 0.06 28.5 0.97 ND 
19 0.20 38.8 0.12 18.3 1.27 ND 
21 0.01 38.1 0.08 11.1 15.90 ND 
22 0.04 39.4 0.03 6.6 4.40 ND 
23 0.31 42.7 0.34 34.0 1.39 p 
24 0.08 36.2 0.11 16.7 2.92 p 
29 0.40 35.7 0.16 20.6 0.69 ND 
32 0.11 25.7 0.15 41.2 0.85 ND 
34 0.17 35.6 0.07 36.0 0.40 ND 
35 0.11 25.00 0.49 82.1 1.36 p 
36 0.12 34.0 0.18 31.6 1.61 p 
42 0.17 37.3 0.13 24.6 1.16 p 
43 0.10 43.8 0.25 24.6 4.50 ND 
48 0.09 43.0 0.03 27.8 0.51 p 
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50 0.12 42.0 0.05 16.9 1.00 ND 
51 0.22 50.0 0.08 36.3 0.50 ND 
52 0.12 41.0 0.15 24.3 2.20 ND 
54 0.10 40.0 0.05 24.1 0.80 N 
55 0.51 46.0 0.31 20.4 3.30 p 
57 0.21 46.0 0.34 19.00 3.90 ND 
58 0.01 38.0 0.05 27.3 7.00 ND 
61 0.14 35.7 0.14 25.3 1.41 ND 
62 0.60 16.0 0.27 26.6 0.30 p 
63 0.09 45.0 0.14 17.8 3.90 p 
64 0.33 45.0 0.15 18.5 1.10 p 
65 0.09 22.0 0.27 39.2 1.68 ND 
66 0.20 47.0 0.13 18.6 0.80 ND 
67 0.27 18.7 0.59 27.6 1.50 ND 
68 0.23 37.0 0.13 20.1 0.96 ND 
69 0.11 39.0 0.11 18.6 0.47 ND 
70 0.12 25.6 0.09 15.5 0.81 p 
71 0.30 56.0 0.16 24.6 0.82 ND 
72 0.27 29.5 0.08 16.1 1.84 ND 
73 0.30 30.4 0.21 19.8 0.93 N 
74 0.27 36.2 0.21 24.3 0.66 p 
75 0.08 38.0 0.08 30.1 1.26 p 
76 0.61 37.0 0.32 28.4 1.46 p 
77 0.17 27.2 0.33 23.4 0.44 ND 
78 0.21 22.0 0.19 23.1 1.10 ND 
79 0.22 30.0 0.21 18.3 0.64 p 
80 0.12 31.2 0.12 37.6 1.21 p 
82 0.82 42.0 0.30 15.3 0.99 p 
85 0.30 28.9 0.27 19.3 0.74 p 
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86 0.05 28.0 0.12 35.8 0.53 p 
89 0.39 22.0 0.33 38.0 0.49 p 
90 0.49 40.0 0.31 22.0 1.20 p 
IgG Index normal < 0.7. Oligoclonal bands: 
P = Positive N = Negative ND = Not Done 
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APPENDIX F: SERUM AND CSF P2-MICROGLOBULIN LEVELS 
Patient No Se 132 CSF 132 Albumin Ratio 
Microglobulin Microglobulin 
6 3.8 4.9 13.7 
13 2.2 4.5 8.7 
31 12.2 2.3 -
50 2.3 3.6 2.8 
51 1.6 2.7 4.4 
52 2.1 2.9 2.9 
54 4.5 3.1 2.5 
55 . 2.5 5.1 11.0 
59 3.3 4.5 -
60 3.6 2.0 -
61 2.3 2.7 4.0 
62 12.7 3.6 
, 
37.5 
63 3.5 4.9 2.0 
64 2.1 7.5 7.3 
65 6.0 4.7 4.0 
66 3.0 3.0 4.2 
68 5.5 6.5 6.2 
70 2.6 6.0 4.6 
71 3.1 7.0 5.3 
75 6.8 1.7 2.1 
82 2.2 5.1 10.7 
85 2.5 10.7 1.7 
86 14.8 16.9 -
88 3.5 9.4 17.7 
89 3.6 3.0 -
�erum & CSF 132 M1croglobulm: normal 1.1 - 2.0 mg/l 
Albumin ratio= CSF/Se ALB (Value > 6.5 abnormal: Eeg-Olofsson et al 1981) 
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APPENDIX G: SURAL NERVE CONDUCTION STUDIES 
Patient No Latency (m/sec) Velocity (m/sec) Amplitude (µV) 
1 4.1 34.1 3.4 
3 2.6 53.8 7.2 
5 3.6 38.8 1.2 
6 4.4 31.8 6.4 
9 3.4 41.1 8.2 
10 NR - -
11 3.2 43.7 5.6 
12 2.5 56.0 16.0 
13 1.8 61.1 16.8 
14 NR - -
16 2.9 38.8 17.0 
21 3.2 43.7 3.0 
22 4.0 35.0 , 2.6 
25 3.2 43.7 18.4 
26 NR - -
27 3.6 38.8 5.8 
28 NR - -
29 3.2 43.7 6.0 
31 3.4 41.4 9.4 
34 3.2 43.7 4.4 
35 2.8 50.0 5.6 
36 NR - -
37 NR - -
39 NR - -
40 2.8 50.0 2.4 
42 NR - -
43 2.6 53.8 2.2 
44 3.4 41.1 6.4 
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45 3.2 43.7 4.8 
46 3.0 46.6 4.2 
47 NR - -
48 NR - -
49 NR - -
50 2.9 48.2 4.0 
51 3.2 0.0 36.8 
52 3.6 0.0 7.8 
53 2.8 50.0 5.0 
54 2.4 58.3 2.6 
55 2.4 58.3 7.0 
56 3.2 43.7 11.2 
57 NR - -
59 NR - -
60 2.8 50.0 17.4 
61 2.8 50.0 3.8 
63 2.4 50.0 9.6 
64 3.8 36.8 4.8 
65 2.9 48.2 6.8 
66 2.5 56.0 4.6 
67 2.6 53.8 7.4 
68 3.2 45.1 6.6 
69 2.4 58.3 3.4 
70 3.3 42.2 5.0 
71 2.9 48.2 18.0 
73 3.1 45.1 13.2 
74 NR - -
75 - 2.8 50.0 6.0 
76 4.4 31.8 3.6 
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77 NR - -
78 2.8 50.0 8.8 
79 3.2 43.7 3.6 
80 3.0 46.6 2.3 
81 3.1 45.1 8.8 
Normal < 3.4 > 41.2 > 5.0
NR = no response: N = normal 
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APPENDIX H: COMMON PERONEAL NERVE CONDUCTION STUDIES 
Patient no Latency Velocity Amplitude 'F'Wave 
(msec) (m/sec) (µV) latency 
(msec) 
1 5.0 36.4 0.96 ND 
3 5.6 37.5 0.48 ND 
5 4.2 50.0 4.40 49.2 
6 4.4 41.6 0.71 50.8 
9 4.5 36.4 4.40 55.6 
10 4.2 43.1 3.16 54.8 
11 3.6 25.5 19.00 42.8 
12 4.6 43.1 4.50 54.0 
13 3.9 56.4 3.68 ND 
14 4.0 45.9 0.64 NR 
16 3.8 47.4 18.00 46.8 
21 4.0 53.5 1.01 0.0 
22 3.5 15.8 5.8 ND 
25 3.2 40.1 2.24 49.0 
26 4.6 43.4 0.84 ND 
27 4.6 41.8 8.7 ND 
28 3.8 40.2 1.0 54.0 
29 4.4 45.6 3.12 ND 
31 8.8 38.6 3.40 62.0 
34 3.8 44.5 10.40 49.2 
35 5.4 40.7 2.68 57.0 
36 5.6 45.0 1.15 48.0 
37 NR - - -
39 4.3 47.7 17.40 32.4 
40 4.0 45.0 1.90 54.8 
42 NR - - -
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44 3.8 41.2 6.40 48.0 
45 4.8 50.0 9.20 50.0 
46 5.6 43.6 6.36 52.6 
47 NR - - -
48 6.2 77.8 3.32 NR 
49 5.8 31.8 4.10 60.8 
53 4.8 38.0 0.89 61.0 
54 3.8 46.8 2.02 ND 
55 4.6 45.1 3.10 54.4 
56 3.6. 36.0 0.79 64.0 
57 3.0 45.1 6.10 53.0 
59 NR - - -
60 3.7 49.3 3.76 48.0 
61 4.2 40.5 8.00 
, 
53.0 
63 3.4 44.5 1.17 47.6 
64 6.2 38.3 10.20 53.0 
65 5.4 37.0 0.28 56.0 
66 3.0 46.3 9.20 52.0 
67 4.4 39.6 12.60 ND 
68 5.2 39.2 1.50 55.6 
69 3.1 58.0 2,50 ND 
70 4.2 36.9 1.28 NR 
71 5.4 46.3 10.50 53.2 
73 5.0 46.8 7.60 48.0 
74 3.2 50.0 6.10 46.4 
75 4.0 47.8 11.00 44.8 
76 NR - - -
77 5.0 30.0 0.27 58.0 
78 6.6 38.6 23.20 44.4 
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79 4.4 39.2 0.91 NR 
80 5.2 43.1 1.70 56.0 
81 5.0 42.3 8.30 56.0 
Normal < 5.1 > 41.0 > 4.17 < 60.0 
NR = no response ; ND = not done 
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APPENDIX I : VISUAL EVOKED RESPONSE STUDIES 
Patient Right eye Right eye Left eye Left eye 
No Latency Amplitude Latency Amplitude 
(msec) (µ.V) (msec) (µ.V) 
1 99.0 9.20 97.0 12.80 
4 102.0 3.60 102.0 3.20 
5 108.0 6.60 108.0 6.80 
6 97.0 14.60 100.0 13.00 
9 99.0 20.40 98.0 16.40 
10 92.0 8.00 114.0 6.40 
16 86.0 0.00 87.0 0.00 
19 99.0 0.00 94.0 0.00 
21 94.0 0.00 96.0 0.00 
25 102.0 7.80 104.0 7.80 
26 108.0 9.80 108.0 9.80 
27 96.0 11.40 97.0 11.40 
28 94.0 6.20 99.0 5.20 
29 105.0 12.80 108.0 5.80 
31 100.0 0.40 103.0 0.30 
35 100.0 5.60 104.0 7.40 
36 99.0 17.40 98.0 12.40 
37 90.0 6.20 91.0 7.20 
39 102.0 10.40 104.0 8.60 
40 97.0 11.40 94.0 11.40 
44 92.0 14.80 92.0 14.80 
45 72.0 11.00 74.0 10.80 
46 90.0 15.00 93.0 16.00 
47 92.0 20.00 97.0 18.40 
49 72.0 18.60 72.0 19.60 
50 81.0 0.00 85.0 0.00 
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51 68.0 10.20 67.0 9.60 
52 116.0 0.00 121.0 0.00 
53 72.0 12.40 72.0 12.50 
54 73.0 11.20 72.0 10.40 
55 109.0 9.40 111.0 7.60 
56 106.0 7.00 106.0 7.00 
57 105.0 11.00 99.0 11.20 
58 108.0 9.20 111.0 8.60 
59 98.0 4.00 98.0 4.00 
60 94.0 10.00 94.0 10.80 
61 76.0 15.20 76.0 15.20 
66 90.0 8.40 99.0 7.00 
68 102.0 9.60 103.0 9.00 
69 93.0 14.20 93.0 14.20 
71 108.0 6.30 106.0 7.20 
72 88.0 3.10 NE NE 
73 94.0 10.20 94.0 7.80 
74 100.0 11.80 96.0 11.00 
77 100.0 6.80 100.0 5.40 
79 114.0 10.00 109.0 6.80 
81 93.0 8.40 96.0 6.60 
83 97.8 0.00 98.0 0.00 
85 110.0 0.00 115.0 0.00 
NE= no eye. 
Abnormal PlO0: Right eye latency > 109.8 msec (Mean + 3 SD) and left eye 
latency > 110.7 msec (mean + 3 SD) 
APPENDIX J(l): RIGHT EAR BRAINSTEM AUDITORY EVOKED 
RESPONSES: ABSOLUTE LATENCIES 
Patient Wave (msec) 
No 
I II III IV V 
1 1.32 2.40 3.64 4.92 6.20 
3 1.56 2.72 3.80 4.76 5.28 
4 1.52 2.68 3.88 5.48 6.04 
5 1.36 2.92 4.12 5.52 6.48 
6 1.48 2.60 3.72 5.04 5.88 
9 1.28 2.64 3.56 4.88 5.76 
10 1.60 2.72 3.56 4.84 5.84 
15 1.40 2.68 3.92 5.20 6.00 
16 1.76 2.68 3.52 4.80 5.68 
19 1.64 2.76 3.76 4.96 4.72 
21 1.44 2.80 4.04 5.36 6.04 
24 1.60 2.44 3.50 NWI 5.32 
25 1.72 2.40 3.52 4.76 5.68 
26 1.52 2.52 3.10 4.12 5.64 
27 1.72 2.68 3.88 5.04 5.72 
29 1.76 2.76 3.84 5.12 6.04 
31 1.68 2.40 3.76 4.64 5.72 
35 1.64 2.96 4.04 5.44 6.20 
36 1.80 2.84 3.64 5.08 5.84 
37 1.48 2.44 3.48 4.80 5.88 
39 1.44 3.20 5.28 6.32 7.44 
40 1.60 2.88 4.00 5.44 6.08 
44 1.60 2.68 3.80 5.12 5.84 
45 1.68 2.84 4.08 5.76 6.08 
46 1.56 2.56 3.76 4.76 5.44 
47 1.48 2.52 3.56 5.08 5.76 
48 1.68 2.76 4.48 5.20 6.24 
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APPENDIX J(l) CONTINUED 
49 1.44 NWI 3.96 5.40 6.20 
50 1.64 2.76 4.12 5.00 5.68 
51 1.56 2.92 3.88 5.04 5.68 
52 1.52 2.52 3.64 5.60 6.04 
53 1.68 2.56 4.20 5.36 6.24 
54 1.44 2.96 4.00 5.16 6.04 
55 1.68 2.56 3.60 0.00 0.00 
56 1.56 2.72 3.84 5.12 5.88 
57 1.36 2.44 3.60 4.80 5.92 
58 NWI 2.76 3.92 5.28 5.76 
59 1.56 2.80 3.92 4.88 5.72 
61 1.48 2.72 3.92 4.96 5.84 
64 1.36 2.68 3.88 5.16 5.76 
65 1.36 2.72 3.84 4.92 5.80 
66 1.52 2.48 3.68 4.72 5.52 
68 1.52 2.80 3.84 5.08 6.00 
69 1.76 2.88 3.80 4.96 6.64 
70 1.72 2.80 4.16 5.16 5.76 
71 1.60 2.68 3.88 4.80 5.96 
72 1.88 2.92 3.92 5.32 6.16 
73 1.96 3.12 4.04 5.16 5.84 
75 1.60 2.80 3.80 4.92 5.56 
76 1.44 3.12 4.24 5.56 6.68 
77 1.56 2.72 3.96 5.28 6.16 
79 1.40 2.88 3.76 4.36 5.32 
80 2.36 3.36 4.40 5.80 6.48 
81 1.64 2.88 4.00 5.32 6.00 
Normal < 1.79 < 2.98 < 4.07 < 5.26 < 5.91 
Mean+ 3� 1J 'I WI = no wave form 1dent1t1ed 
APPENDIX J (2): RIGHT EAR BRAINSTEM AUDITORY EVOKED 
RESPONSES: INTERVAL LATENCIES 
Patient no Intervals (msec) 
I - III III - V I - V 
1 2.88 2.56 4.88 
3 2.20 1.56 3.72 
4 2.16 2.12 4.56 
5 2.76 2.36 5.16 
6 2.20 2.16 4.40 
9 2.32 2.16 4.48 
10 1.69 2.24 4.24 
15 2.48 2.05 4.56 
16 1.80 2.16 3.92 
19 2.12 1.96 4.08 
21 2.60 2.08 4.60 
24 1.96 1.68 3.72 
25 1.80 2.16 3.96 
26 1.84 2.20 4.12 
27 2.16 1.84 4.00 
29 2.08 2.24 4.32 
31 2.08 4.04 1.96 
35 2.40 2.16 4.56 
36 1.84 2.20 4.04 
37 2.00 2.40 4.40 
39 3.84 2.16 6.00 
40 2.36 2.16 4.48 
44 2.20 2.04 4.24 
45 2.40 2.00 3.80 
46 2.20 1.68 3.88 
47 2.08 2.20 4.28 
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48 2.80 1.76 4.56 
49 2.52 2.24 0.00 
50 2.48 1.56 4.04 
51 2.32 2.80 4.12 
52 2.12 2.40 4.52 
53 2.52 2.04 4.56 
54 2.56 2.04 4.60 
57 2.24 2.32 4.56 
58 - 1.84 -
59 2.36 1.80 4.16 
61 2.40 1.92 4.36 
64 2.52 1.88 4.40 
65 2.48 1.96 4.44 
66 2.16 1.84 4.00 
68 2.32 2.16 4.48 
69 2.04 2.84 3.88 
70 2.44 1.60 4.04 
71 2.28 2.08 4.36 
72 2.04 2.84 4.18 
73 2.08 1.80 3.88 
75 2.20 1.76 3.96 
76 2.80 2.44 5.24 
77 2.40 2.20 4.60 
79 2.36 1.56 3.92 
80 2.04 2.08 4.12 
81 2.36 2.00 4.36 
Normal < 2.44 < 2.30 < 4.52 
APPENDIX J(3): LEFT EAR BRAINSTEM AUDITORY EVOKED 
RESPONSES: ABSOLUTE LATENCIES 
Patient no Wave (msec) 
I II III IV V 
1 1.52 2.48 3.68 4.60 5.20 
3 1.52 2.76 3.76 4.88 5.44 
4 1.56 2.80 3.88 5.28 6.16 
5 1.28 2.68 4.00 5.28 6.16 
6 1.44 2.56 3.52 4.84 5.84 
9 1.36 2.44 3.60 4.76 5.84 
10 1.36 2.56 3.56 4.64 5.80 
15 1.52 2.80 3.84 5.16 6.00 
16 1.72 2.80 3.80 4.92 5.84 
21 1.52 2.68 4.04 5.32 6.04 
24 1.60 NWI 3.72 4.76 5.88 
25 1.76 2.52 3.72 4.76 4.52 
26 1.52 2.72 4.16 5.68 7.12 
27 1.56 2.84 4.04 5.20 5.80 
29 1.72 2.56 4.00 5.12 6.08 
31 1.76 2.60 3.40 5.00 5.48 
35 1.60 2.96 4.08 5.28 6.16 
36 1.68 2.64 3.64 4.72 5.76 
37 1.56 2.52 3.56 5.00 5.76 
39 1.32 2.88 4.12 5.00 5.88 
40 1.40 2.80 4.08 6.64 6.12 
44 1.60 2.48 3.76 5.12 5.84 
45 1.28 3.00 4.04 5.48 6.04 
46 1.48 2.56 3.72 5.25 6.24 
47 1.52 2.72 5.84 5.08 6.08 




APPENDIX J (3) CONTINUED 
49 1.48 NWI 3.96 5.60 6.28 
50 1.52 NWI 4.28 5.16 5.60 
51 1.20 2.92 4.04 5.04 5.36 
52 1.36 2.44 3.44 4.76 3.20 
53 1.44 2.44 3.64 4.80 5.92 
54 1.68 2.76 3.80 4.80 5.72 
55 1.52 �.92 0.00 0.00 0.00 
56 1.08 2.52 3.64 5.00 5.80 
57 1.60 2.56 3.72 4.96 5.92 
61 1.48 2.72 3.84 5.00 5.80 
64 1.56 2.64· 3.76 4.80 5.80 
65 1.35 2.68 3.88 4.96 5.84 
66 1.40 2.48 3.44 4.52 5.36 
68 1.52 2.80 3.84 5.20 6.00 
69 1.68 2.96 3.72 5.04 5.76 
70 1.56 2.92 4.28 5.64 6.52 
71 1.36 2.68 4.04 5.12 5.84 
72 1.72 2.80 4.00 5.12 5.88 
73 1.84 2.92 4.04 5.08 5.96 
74 1.20 2.56 3.84 5.24 5.88 
75 1.52 2.72 3.84 4.96 5.60 
76 1.48 3.04 4.12 5.52 6.36 
77 1.36 2.80 3.88 5.08 5.88 
79 1.40 2.76 3.68 4.64 5.28 
80 2.48 3.80 5.00 6.28 6.84 
81 1.56 2.72 3.93 5.40 6.16 
Normal < 1.78 < 2.98 < 4.07 < 5.26 < 5.91 
NWI: No wave identified. 
APPENDIX J(4).: LEFT EAR BRAINSTEM AUDITORY EVOKED 
RESPONSES: INTERVAL LATENCIES 
Patient No Interval (msec) 
I - III III - V I - V 
1 2.16 1.48 3.68 
3 2.24 1.68 3.92 
4 2.32 2.24 4.68 
5 2.76 2.12 4.88 
6 2.12 2.32 4.40 
9 2.28 2.20 4.44 
10 . 2.24 2.24 4.44 
15 2.32 2.12 4.48 
16 2.08 2.08 4.12 
21 2.52 2.04 4.52 
24 2.12 2.16 
, 
4.36 
25 1.96 2.00 3.96 
26 2.64 3.00 5.60 
27 2.48 1.76 4.24 
29 2.28 2.08 4.36 
31 1.60 3.76 2.16 
35 2.48 2.08 4.56 
36 1.96 2.12 4.08 
37 2.00 2.22 3.20 
39 2.80 1.76 4.56 
40 2.64 1.92 4.68 
44 2.16 2.08 4.24 
45 2.74 2.00 4.76 
46 2.24 2.52 4.76 
47 2.32 2.24 4.56 
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48 2.16 1.84 4.00 
49 2.48 2.32 4.80 
50 2.76 1.32 4.08 
51 2.84 1.46 4.30 
52 2.08 1.76 3.84 
53 2.20 2.28 4.48 
54 2.12 1.92 4.04 
57 2.12 2.20 4.32 
61 2.36 1.90 4.32 
64 2.20 2.04 ,4.24 
65 2.52 1.96 4.48 
66 2.04 1.92 3.96 
68 2.32 2.16 4.48 
69 2.04 2.04 4.08 
70 2.72 2.24 4.96 
71 2.68 1.80 4.48 
72 2.28 1.88 4.16 
73 2.20 1.92 4.12 
74 2.64 2.04 4.68 
75 2.32 1.76 4.08 
76 2.64 2.24 4.88 
77 2.52 2.00 4.52 
79 2.28 1.60 3.88 
80 2.52 1.84 4.36 
81 2.36 2.24 4.60 
Normal < 2.44 < 2.30 < 4.52 
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APPENDIX K: METHODOLOGY FOR PCR FROM PARAFFIN 
EMBEDDED TISSUE 
DNA EXTRACTION 
Total cellular DNA was extracted from formalin fixed paraffin embedded blocks 
of the patient's spinal cord. Two 5 - 10 micron thick sections were cut using a new 
dry microtome knife and placed in a sterile 1.5ml microfuge tube. One ml of 
Xylene was added to each tube and thoroughly mixed for 30 minutes. The mixture 
was pelleted with a microfuge for 5 minutes and the Xylene extraction repeated. 
To the pellet 0.5ml of 100% ethanol was added and mixed. Ethanol was removed 
and the sample re-extracted with ethanol and dried under vacuum. One hundred 
to 200ml of digestion buffer containing 200 ug/ml of proteinase K (in 50mM Tris 
(pH8.5), 1 mM EDTA, plus 1% Laureth 12 (Mazer Chemicals, Gurne 11) or 0.5% 
Tween 20) was added to the mixture and incubated for 3 hours at 55°C. Digestion 
was stopped with 10 minute incubation at 95°C before pelleting and storage of 
supernatant at -20°C. 
POLYMERASE CHAIN REACTION ASSAY 
The primers used to detect proviral HTLV-1 were targeted towards the viral "gag" 
glue. These primers, 5' -CCGCGACCGCCCCGGGGGCTGG-3' (WWlO) and 
5'-TCACCCGGCCGGGGTATCCT-3' (WWll) define a 205 bp fragment 
extending from +860 to + 1064 in the HTLV-1 proviral genome. Primer WWlO 
was 32P-end labelled using T4 polynucleotide kinase (specific activity 2 x 107
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cpm/pM) and 1.5 x 106 cpm (0,lpM) was added to the PCR assay mixture. The 
PCR mixture (50 ul final volume) contained lOmM Tris pH8.3; 30mM KCl; 2.0mM 
MgCl. 0.01% gelatin; 0.1% Triton x-100, 12pM of each primer including the 
labelled wwlO primer, 0.2mM each of alpha ATP, alpha CTP, alpha GTP and alpha 
TfP, and the extracted template DNA. PCR was performed using the Ericomp 
(San Diego CA) temperature cycler for 30 cycles (denaturing at 94°C, annealing 
and extension at 65°C). Following the first denaturing step 2.5 U of Taq DNA 
polymerase (Promega Corp; Madison WI) was added to each reaction and the 
sample was overlayed with a drop of mineral oil. 
To normalise for the amount of DNA contained in each sample PCR was 
performed to assay for the glyceraldehyde 3-phosphate dehydrogenase gene. The 
PCR assay reaction mixture and conditions were identical to that described for 
HTLV-1 gag, except for the absence of Triton X-100 and adjustment of the final 
concentration of MgCl to 14mM. 
The PCR products were resolved on a 6% acrylamide gel, dried and exposed to 
Kodak XAR film at -80°C for 0.25 to 16 hours. Hae III cut GX-174 DNA 32P-end 
labelled fragments served as molecular weight markers. 





SEX: 1 = MALE 
AGE 
2 = FEMALE 
MARITAL STATUS: 1 = SINGLE 2 = MARRIED 
3 = SEPARATED/DIVORCED 
BLOOD TRANSFUSION: YES = 1 NO = 2
NO. OF UNITS 
TRIBAL SCARIFICATIONS; YES = 1 NO = 2 
OCCUPATION 
OPTIONAL QUESTIONS: 
AGE AT FIRST SEXUAL EXPERIENCE 






ANY NEUROLOGICAL PROBLEM: YES = 1 NO = 2 CJ 
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